Page last updated: 2024-08-24

atorvastatin and Cardiovascular Diseases

atorvastatin has been researched along with Cardiovascular Diseases in 477 studies

Research

Studies (477)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.21)	18.2507
2000's	214 (44.86)	29.6817
2010's	214 (44.86)	24.3611
2020's	48 (10.06)	2.80

Authors

Authors	Studies
Aschenbrenner, DS	1
Chowdhury, EK; Curtis, AJ; Ernst, ME; McNeil, JJ; Murray, AM; Nelson, MR; Reid, CM; Ryan, J; Tonkin, AM; Wolfe, R; Woods, RL; Zhou, Z; Zoungas, S	1
Borghi, C; Levy, BI	1
Bjourson, AJ; English, AR; Horigan, G; Kelly, C; McClean, PL; McGuigan, DH; O'Kane, M; Prasad, B; Shukla, P	1
Duarte, K; Fauler, G; Fellström, B; Girerd, N; Jardine, AG; März, W; Massy, ZA; Rossignol, P; Sadiku, S; Scharnagl, H; Schmieder, RE; Silbernagel, G; Zannad, F	1
Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG	1
Godec, T; Gupta, A; Norling, LV; Oggero, S; Perretti, M; Pinto, AL; Reutelingsperger, C; Schurgers, LJ; Sever, P; van Gorp, R	1
Alaylioglu, M; Dogan, AS; Dursun, E; Gezen-Ak, D; Onal, B; Ugurlucan, M; Yenmis, G	1
Alexander, LM; Dillon, GA; Flores, VA; Serviente, C; Stachenfeld, N; Stanhewicz, AE	1
Alonso Garcia, A; Andres, V; Barczi, G; Baviera, M; Beghi, E; Bejot, Y; Bhatt, DL; Bueno, H; Castellano, JM; Colivicchi, F; Collier, T; Cordero, A; Di Fusco, SA; Doehner, W; Domingo-Fernández, A; Ecarnot, F; Fernandez Alvira, JM; Fernandez Ferro, J; Fernandez-Ortiz, A; Foresta, A; Fuster, V; Ibañez, B; Kasprzak, M; Linhart, A; Lopez, N; Lozano, I; Lubanda, JC; Marin Ortuño, F; Merkely, B; Meyer, A; Ojeda-Fernandez, L; Owen, R; Perel, P; Pocock, SJ; Ponikowski, P; Proietti, M; Quesada, AJ; Rodriguez-Manero, M; Roncaglioni, MC; Sanchez, PL; Schiele, F; Schoos, MM; Simon, T; Van de Werf, F; Vazquez Rodriguez, JM; Vivas, D	1
Al-Mahayri, ZN; Al-Maskari, F; Ali, BR; AlKaabi, J; Alqasrawi, MN; Altoum, SM; AlZaabi, A; Badawi, S; George, L; Hamza, D; Jamil, G; Khasawneh, LQ; Ouda, H; Patrinos, GP	1
Kowalcze, K; Krysiak, R; Okopień, B	4
Cinque, G; Dowling, LM; Njoroge, W; Sulé-Suso, J; Xie, B; Yang, Y	1
Fomin, VV; Mironova, OI; Vasin, AA	1
Ansbro, É; Aoun Bahous, S; Boulle, P; Masri, S; Molfino, L; Perel, P; Prieto-Merino, D; Willis, R	1
Susekov, AV	1
Chen, WM; Shia, BC; Wu, SY; Yu, JM	1
Al Zoubi, S; Al-Hawamdeh, M; Alrashdan, R; Ayyad, D; Gharaibeh, L; Sartawi, H	1
Baker, JV; Gorelick, RJ; Krishnan, S; Laidlaw, E; Lisco, A; Manion, M; Migueles, SA; Mystakelis, HA; Poole, A; Rupert, A; Sereti, I; Welker, JL; Wilson, E	1
Adams, SP; Alaeiilkhchi, N; Tasnim, S; Wright, JM	1
García-Rivero, AA; González-Tovar, NB; Rivas-Ruíz, R; Rivera-Lara, P; Villegas-Quintero, VE	1
Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N	1
Backer, G; Bacquer, D; Clays, E; Kotseva, K; Reiner, Ž; Rydén, L; Smedt, D; Tokgözoğlu, L; Wood, D	1
Daskalopoulou, SS; Gasbarrino, K; Hafiane, A; Zheng, H	1
Caspar, AT; Hemmer, S; Meyer, MR; Wagmann, L	1
Civeira, F; Fuentes, F; Laclaustra, M; Marco-Benedi, V; Ortega, E; Perez-Calahorra, S; Pinto, X; Plana, N; Sanchez-Hernandez, RM	1
Lazris, A; Roth, AR	1
González-Juanatey, JR; Oudovenko, N; Tamargo, J; Torres, F; Weisser, B	1
Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J	1
Tůmová, E; Vrablík, M	1
Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M	1
Alexander, JH; Berwanger, O; Damiani, LP; de Barros E Silva, PGM; Granger, CB; Lopes, RD; Santos, RHN	1
Fu, G; Li, Y; Luan, Y; Lv, Q; Xu, T; Zhang, W; Zhao, L	1
Cong, H; Hou, K; Hu, Y; Li, R; Wang, L; Zhai, C; Zhang, J; Zhang, R; Zhang, Y	1
Adams, SP; Alaeiilkhchi, N; Wright, JM	1
Kondratenko, S; Kukes, V; Melnikov, E; Shikh, E; Zozina, V	1
Hoang, T; Kim, J	1
Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W	1
Abtahi, F; Anushiravani, A; Fattahi, MR; Gandomkar, A; Malekzadeh, F; Malekzadeh, R; Malekzadeh, Z; Merat, S; Moghadami, M; Mohammadkarimi, V; Moini, M; Mortazavi, R; Poustchi, H; Sadeghi Boogar, S; Sepanlou, SG	1
Zlatohlávek, L	1
Wu, Y; Xu, Y	1
Kanayama, M; Miyashita, Y; Moroi, M; Nagayama, D; Ohira, M; Saiki, A; Sato, N; Shimizu, K; Shirai, K; Takahashi, M; Tatsuno, I; Watanabe, Y; Yamaguchi, T	1
Cha, KS; Chae, SC; Choi, BG; Choi, CU; Choi, JY; Jang, WY; Jeong, MH; Kang, DO; Kim, EJ; Kim, JW; Kim, W; Na, JO; Oh, SK; Park, CG; Park, Y; Rha, SW; Seo, HS; Seong, IW; Yoon, CH	1
Ancion, A; Lancellotti, P; Scheen, AJ	1
Hoogeveen, RM; Kaiser, Y; Kroon, J; Moens, SJB; Stroes, ESG; Verberne, HJ; Verweij, SL; Vogt, L	1
Kobayashi, J	1
Iimuro, S; Matsuyama, Y; Shinozaki, T; Yamamuro, S	1
Du, H; Hu, J; Liu, H; Yang, C; Yang, G; Zhao, H	1
Genser, B; März, W; Wanner, C	1
Borovac, JA; Bozic, J; D'Amario, D; Glavas, D; Kumric, M; Leth-Olsen, M; Schwarz, K	1
Badhan, RK; Dennison, TJ; Mohammed, AR; Smith, JC	1
Bonsu, KO; Buabeng, KO; Kadirvelu, A; Owusu, IK; Reidpath, DD	1
Bangalore, S; DeMicco, DA; Fayyad, R; Laskey, R; Messerli, FH; Waters, DD	1
Hsieh, HC; Hsu, JC; Lu, CY	1
DeMicco, DA; Fayyad, R; Laskey, R; Ports, WC; Wolk, R	1
Radermecker, RP	1
Cho, GY; Jung, JH; Kim, HK; Kim, HL; Kim, YJ; Lee, SP; Park, JB; Sohn, DW; Yoon, YE	1
Ferreira, J; Giugliano, RP; Huber, K; Keech, A; Lewis, BS; Murphy, SA; Pedersen, TR; Pineda, AL; Sabatine, MS; Sever, PS; Somaratne, R; Tokgozoglu, SL	1
Armitage, J; Beaumont, D; Brack, K; Goldacre, B; Herrett, E; MacDonald, T; Prowse, D; Roberts, I; Shakur-Still, H; Smeeth, L; Staa, TV; Williamson, E; Youssouf, N	1
Anzalone, DA; Evans, KA; Johnston, S; Lewis, SJ; Malangone-Monaco, E; Olufade, T	1
Kobalava, ZD; Villevalde, SV; Vorobyeva, MA	1
Alexander, JH; Armaganijan, LV; Baldissera, F; Barbosa, LM; Beraldo de Andrade, P; Berwanger, O; Bienert, IRC; Borges de Oliveira, JA; Bosso, CE; Cavalcanti, AB; Dall Orto, FTC; Damiani, LP; de Barros E Silva, PGM; Egydio, FM; Giraldez, RRCV; Granger, CB; Guimarães, HP; Jesuíno, IA; Kalil, RAK; Laranjeira, LN; Lopes, RD; Mangione, JA; Mattos, LA; Nascimento, BR; Pereira, SB; Polanczyk, CA; Rech, RL; Santos, LM; Santos, RHN; Santucci, EV; Sousa, ACS; Sousa, AGMR; Sousa, JEMR; Sposito, AC	1
Alvares, J; Bennie, M; de Acurcio, FA; do Nascimento, RCRM; Godman, B; Gomes, IC; Guerra, AA; Kurdi, AB	1
Filardi, PP; Maggioni, AP	1
Bergheanu, SC; Bodde, MC; Jukema, JW; Liem, AH; Lijfering, WM; Mertens, B; Sattar, N; van der Laarse, A; Welsh, P	1
Battistoni, A; Citoni, B; Coluccia, R; De Biase, L; Ferrucci, A; Figliuzzi, I; Miceli, F; Musumeci, MB; Presta, V; Tocci, G; Volpe, M	1
Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK	4
González-Juanatey, JR	1
Bayliss, M; Fontana, V; Pirmohamed, M; Santoyo Castelazo, A; Turner, RM; Whalley, S	1
Amérand, A; Desfontis, JC; Didier, R; Farhat, F; Gilard, M; Mallem, MY; Mansourati, J; Moisan, C; Philouze, C; Pichavant-Rafini, K; Theron, M; Tissier, F	1
Krysiak, R; Okopień, B; Szkróbka, W	2
Collier, T; Godec, T; Gupta, A; Mackay, J; Pocock, S; Poulter, N; Sever, P; Whitehouse, A	1
Ashcroft, JA	1
Adam, S; Durrington, PN; Soran, H	1
Jonnalagadda, VG	1
Eleftheriadou, I; Grigoropoulou, P; Sykara, M; Tentolouris, A; Tentolouris, N; Tsilingiris, D; Vlachopoulos, C	1
Fang, H; Hu, J; Li, M	1
Barter, PJ; DeMicco, DA; Fayyad, R; Hui, N; Januszewski, AS; Jenkins, AJ; Kaakoush, NO; Keech, AC; Ong, KL; Rye, KA; Waters, DD; Xu, A	1
Guan, S; Li, W; Wang, B; Zhang, Y	1
Aschmann, HE; Puhan, MA; Yebyo, HG	1
Andersen, AM; Bergan, S; Husebye, E; Munkhaugen, J; Vethe, NT	1
Dejene, SZ; Desai, RJ; Dutcher, SK; Franklin, JM; Gagne, JJ; Gopalakrishnan, C; Levin, R; Sarpatwari, A; Schneeweiss, S	1
Katsiki, N; Mantzoros, C	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Cannon, CP; Khan, I; Klimchak, AC; Reynolds, MR; Rosenson, RS; Sanchez, RJ; Sasiela, WJ	1
Choi, CU; Kim, IW; Kim, JH; Kim, K; Kwak, A; Oh, JM	1
Chan, P; Liu, Z; Ma, YB; Tomlinson, B; Zhang, Y	1
Liao, KP; Solomon, DH	1
Armitage, J; Belch, JJF; Kitas, GD; Nightingale, P; Sattar, N; Symmons, DPM	1
Bednarska-Czerwińska, A; Kowalcze, K; Krysiak, R; Okopień, B	1
Chen, H; Chen, X; Chen, Y; Dong, J; Ge, J; Jiang, XC; Wang, L; Zhang, X	1
Bahrey, D; Demoz, GT; Hagazy, K; Kasahun, GG; Kinfe, DG; Niriayo, YL; Tasew, H; Wahdey, S	1
Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P	1
Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y	1
Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH	1
Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM	1
Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D	1
Berberich, R; Dieplinger, B; Dieplinger, H; Ikewaki, K; Koenig, P; Kronenberg, F; Nakada, Y; Neyer, U; Salmhofer, H; Schwaiger, JP; Zitt, E	1
Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR	1
Steurer, J	1
Medvedeva, EA; Seleznev, EI; Shchukin, IuV	1
Alderson, P; Lewis, SR; Nicholson, A; Sanders, RD; Smith, AF	1
Chang, CL; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P	1
Blumenthal, RS; Martin, SS; Ndumele, CE	1
Reiner, Ž; Tedeschi-Reiner, E	1
Groenemeijer, M; Nanayakkara, PW; Scheffer, PG; Schindhelm, RK; Simsek, S; Smulders, YM; van Verschuer, VM	1
Dabrowski, M; Wiliński, J	1
Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP	2
Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW	1
Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C	1
Ge, J; Jang, Y; Ji, C; Kim, YJ; Lam, W; Zhu, J	1
Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y	1
Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H	1
Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C	1
Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N	1
Marques-Vidal, P; Preisig, M; Vaucher, J; Vollenweider, P; Waeber, G	1
Aarnio, E; Helin-Salmivaara, A; Huupponen, R; Korhonen, MJ; Lavikainen, P	1
Hisdal, J; Holme, I; Ikdahl, E; Kvien, TK; Pedersen, TR; Rollefstad, S; Semb, AG	1
Aguirre, AC; Barbosa, SP; Bianco, HT; do Amaral, JB; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN	1
Bangalore, S; DeMicco, DA; Fayyad, R; Hovingh, GK; Laskey, R; Vogt, L; Waters, DD	1
Lozzi, A	1
Marrett, E; Neff, DR; Ramey, DR; Tershakovec, AM; Tomassini, JE; Zhang, NJ; Zhang, Q; Zhao, C	1
Evdakimova, AA; Iakovenko, EI; Mamedov, MN; Sharvadze, GG; Toguzova, ZA	1
Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B	1
Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T	1
Al Zhrany, N; Atwill, M; Bennaceur, K; Breault, D; Hoffmann, J; Keavney, B; Richardson, G; Saretzki, G; Spyridopoulos, I; von Zglinicki, T	1
Doerfer, J; Grulich-Henn, J; Grünert, SC; Holder, M; Krebs, A; Lichte, K; Schmidt-Trucksäss, A; Schwab, KO; Stier, B; Winkler, K; Wöhrl, J	1
Blumenthal, RS; Greenland, P; Polonsky, TS	1
Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN	1
Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG	1
Ebisawa, S; Ikeda, U; Izawa, A; Kagoshima, M; Kashima, Y; Kitabayashi, H; Koyama, J; Miura, T; Miyashita, Y; Sakurai, S; Tomita, T; Yamamoto, H	1
Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK	1
Sundell, KA; Trusell, H	1
Dohi, T	1
Ye, YC; Zhang, SY; Zhao, XL	1
Ambegaonkar, BM; Cao, X; Ejzykowicz, F; Mavros, P; Ramey, DR; Sajjan, S; Tunceli, K	1
Stimac, D; Vojvodić, Z	1
Gilowski, W; Krysiak, R; Okopien, B	2
Arsenault, BJ; Bao, W; Byun, YS; DeMicco, D; Laskey, R; Lee, JH; Tsimikas, S; Witztum, JL; Yang, X	1
Kritharides, L; Nicholls, SJ	1
Bao, W; Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Preston, GM; Schalkwijk, CG; Soedamah-Muthu, SS; Stehouwer, CD	1
Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE	1
Baumgartner, I; Drechsler, C; Fauler, G; Genser, B; Grammer, TB; Krane, V; März, W; Ritz, E; Scharnagl, H; Silbernagel, G; Wanner, C	1
Bays, H; Donahue, S; Gaudet, D; Gouni-Berthold, I; Hanotin, C; Robinson, J; Ruiz, JL; Watts, GF; Weiss, R; Zhao, J	1
Almeida, S; de Souza, JA; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Menin, A; Pires, RC; Smiderle, L; Van Der Sand, CR; Van Der Sand, LC	1
Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W	1
Hemming, K; Jafari, E; Khoshnia, M; Malekzadeh, R; Marshall, T; Merat, S; Nateghi, A; Poustchi, H; Radmard, AR; Shiravi Khuzani, A	1
Cheng, W; Gao, F; Ma, Q; Wang, J; Yang, Q; Zhai, G; Zhang, L; Zhou, Y	1
Breazna, A; Deedwania, PC; DeMicco, DA; Shepherd, J	1
Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M	1
Berns, SA; Bondareva, IN; Smakotina, SA; Zelendinova, AR	1
Banach, M; Bittner, V; Hovingh, GK; Kastelein, JJ; Lip, GY; Mikhailidis, DP; Ray, K; Rysz, J; Sahebkar, A; Serban, C; Undas, A; Ursoniu, S; Watts, GF	1
Barrios, V; Escobar, C	1
Castellano, JM; Fuster, V; Tamargo, J	1
Dieplinger, H; Drechsler, C; Kollerits, B; Krane, V; Kronenberg, F; Lamina, C; März, W; Ritz, E; Wanner, C	1
Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P	1
Cheng, G; Li, H; Li, R; Sun, S; Wang, C; Zhang, S; Zou, M	1
Gutjahr-Lengsfeld, LJ; Krane, V; Mann, JF; März, W; Schmidt, KR; Swoboda, F; Wanner, C	1
Tietge, UJ	1
Scheen, AJ	5
Abarca, B; González-Juanatey, JR; Llisterri, JL; Lobos, JM; Mostaza, JM	1
Baeten, DL; Bernelot Moens, SJ; Nederveen, AJ; Nurmohamed, MT; Strang, AC; Stroes, ES; van der Valk, FM; Verberne, HJ; Verweij, SL	1
Karmann, B; Laufs, U; Pittrow, D	1
Baryshnikova, GA; Blohina, OE; Chorbinskayva, SA; Pokutniy, NF; Stepanova, II; Zverkov, IV	1
Seftel, AD	1
Bertrand, ME; Mourad, JJ; Vlachopoulos, C	1
Arsenault, BJ; DeMicco, DA; Kastelein, JJ; Kohli, P; Lambert, G; Laskey, R; Messig, MM; Waters, DD	1
Samura, B	1
Barrios, V; Castellano, JM; Cosin-Sales, J; Fuster, V; Gracia, A; Kaskens, L; Ruiz, JE; Zsolt, I	1
Banach, M; Blaha, MJ; Chruściel, P; Jones, SR; Lip, GY; Martin, SS; Mikhailidis, DP; Mosteoru, S; Pencina, MJ; Ray, KK; Rembek-Wieliczko, M; Rysz, J; Sahebkar, A; Serban, MC; Toth, PP; Ursoniu, S	1
Baccara-Dinet, MT; Bergeron, J; Langslet, G; Manvelian, G; Moriarty, PM; Rader, DJ; Roth, EM; Zhao, J	1
Goh, CC; Goh, SC; Koh, KH; Koh, YL; Tan, NC	1
Chen, FC; Yeh, KL	1
Gilowska, M; Krysiak, R; Okopień, B	1
Harrison, J; Jackson, R; Kerr, A; Mehta, S; Wells, S	1
Casula, M; Catapano, AL; Corrao, G; Merlino, L; Scotti, L; Tragni, E	1
Briel, M; Ferreira-González, I; Jakob, T; Nordmann, AJ; Schandelmaier, S	1
Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD	1
Abarca, B; Alemán, JJ; Baron-Esquivias, G; Egocheaga, I; Galve, E; Garcia-Moll, FX; González-Juanatey, JR; Lidón, RM; Llisterri, JL; Lobos, JM; Millán, J; Mostaza, JM; Pallares, V; Sánchez, PL; Suárez, C	1
Bon, I; Borderi, M; Calza, L; Colangeli, V; Contadini, I; Magistrelli, E; Re, MC; Viale, P	1
Bjorndahl, TC; Caplice, NM; Fitzgerald, GF; London, LE; Mandal, R; Murphy, K; Ross, RP; Ryan, PM; Shanahan, F; Stanton, C; Wishart, DS	1
Benner, JS; Foody, JM; Joyce, AT; Liu, LZ; Rudolph, AE	2
Colin, X; Lafuma, A; Solesse, A	1
Todd, DJ	1
Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL	1
Martin, J	1
Vogel, RA; Willke, RJ; Zhou, S	1
Mehlsen, J	1
Benner, JS; Foody, JM; Jeffers, BW; Joyce, AT; Liu, LZ	1
Fitchett, DH; Goodman, SG; Langer, A	1
Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF	1
Carmena, R; Chu, P; Drummond, M; Graff, J; Greten, H; Pandya, A; Shepherd, J; Taylor, DC; Thompson, D; Weinstein, MC; Wenger, N	1
Kékes, E	1
Barrios, V; Echarri, R; Escobar, C	1
Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B	1
Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M	1
Bittner, V; Breazna, A; DeMicco, DA; Greten, H; Grundy, SM; Johnson, C; LaRosa, JC; Waters, DD	1
Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L	1
Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P	1
Cziraky, M; Grochulski, D; Hoy, T; Jacobson, TA; Kuznik, A; Wertz, DA	1
Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V	1
Hoeger, KM	1
Goldstein, MR; Mascitelli, L; Pezzetta, F	1
Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C	1
Lüscher, TF	1
Holmberg, B; Stegmayr, BG	1
Koren, MJ; Kuznik, A; Mullins, CD; Rattinger, GB	1
Hirata, K; Inoue, N; Kawashima, S; Masano, T; Nakajima, K; Nishimura, K; Sasaki, N; Satomi-Kobayashi, S; Shinohara, M; Sugiyama, D; Takaya, T; Takeda, M; Tawa, H; Toh, R; Yamashita, T; Yokoyama, M	1
Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H	1
Tokgözoğlu, L	1
Kültürsay, H	1
Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD	1
Bangalore, S; Devabhaktuni, M	1
Chu, P; Goetghebeur, M; Merikle, E; Pandya, A; Taylor, DC; Wagner, M	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA	1
Deedwania, P; Singh, V	1
Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F	1
Davy, KP; Dengo, AL; Orr, JS; Rivero, JM	1
Castelli, P; Castiglioni, L; Consuelo Maio, R; Cosentino, M; De Leo, A; Guasti, L; Lecchini, S; Legnaro, M; Marino, F; Maroni, L; Piffaretti, G; Rasini, E; Schembri, L; Tozzi, M; Venco, A	1
Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K	1
Claudel, T; Fauler, G; März, W; Putz-Bankuti, C; Scharnagl, H; Sourij, H; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M; Wascher, TC; Winkler, K	1
Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M	1
Ko, SK; Liew, D; Park, HJ	1
Birnbaum, H; Connolly, C; Ivanova, J; Kidolezi, Y; Kuznik, A; Signorovitch, J; Simpson, RJ	1
Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S	1
Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K	1
Nissen, SE	1
Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M	1
Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW	1
Faergeman, O; Hyde, CL; Lira, M; Macinnes, A; Mazzarella, RA; Paciga, SA; Sanders, FA; Thompson, JF; van Wijk, DF; Wood, L	1
Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M	1
Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ	1
Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J	1
Lacchini, R; Silva, PS; Tanus-Santos, JE	1
Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R	1
Tuttle, KR	1
Ahn, TH; Ahn, YK; Bae, JH; Baek, SH; Choi, DJ; Choi, YJ; Hong, SJ; Hong, TJ; Hur, SH; Ihm, SH; Jang, YS; Kim, BS; Kim, DI; Kim, HS; Kim, YJ; Lee, CW; Lee, SH; Lee, SU; Park, DG; Ryu, KH; Seung, KB	1
Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ	1
Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P	1
Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H	1
Derosa, G; Maffioli, P	1
Chapman, RH; Roberts, CS; Yeaw, J	1
Geleedst-De Vooght, M; Jansen, P; Maitland-van der Zee, AH; Mantel-Teeuwisse, A; Schalekamp, T	1
Huang, QY; Liu, L; Shu, J; Xu, DY; Zhao, SP	1
Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN	1
Daida, H; Hiro, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Murohara, T; Nakagawa, Y; Ohashi, T; Ozaki, Y; Shibata, R; Yamagishi, M	1
Acharjee, S; Cannon, CP	1
Birnbaum, H; Ivanova, J; Kuznik, A; Ramakrishnan, K; Signorovitch, J; Simpson, RJ	1
Boulanger, L; Chen, SY; Mardekian, J; Rao, P; Rublee, DA; Wu, N	1
Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH	1
Wierzbicki, AS	1
Meek, CL; Pathmanathan, H; Ramsbottom, T; Reston, JD; Viljoen, A	1
Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K	1
Buch, J; Caulfield, MJ; Collier, DJ; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H	1
Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J	1
Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS	1
Blann, AD; Jaumdally, RJ; Lip, GY; Varma, C	1
Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Kakafika, A; Karagiannis, A; Kolovou, GD; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Petridis, D; Tziomalos, K	1
Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K	1
Jialal, I; Kaur, J	1
Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S	1
Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI	1
Fujita, K; Hasuike, T; Horimatsu, T; Maruyama, T; Masuda, S; Miki, K; Nishibori, Y; Takada, M	1
Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K	1
Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C	1
Della-Morte, D; DeRosa, JT; Elkind, MS; Gutierrez, J; Lorenzo, D; McClendon, MS; Ratchford, EV; Rundek, T; Sacco, RL	1
Abdulhalim, AM; Grabner, M; Johnson, W; Kuznik, A; Mullins, CD	1
Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K	1
Buikema, A; Kulakodlu, M; Kuznik, A; Potash, J; Swindle, JP	1
Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD	1
Arsenault, BJ; Barter, P; Boekholdt, SM; Chatterjee, A; Deedwania, P; DeMicco, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; LaRosa, JC; Pedersen, TR; Waters, DD	1
Saito, Y	1
Teramoto, T	1
Chan, WC; Hopkins, R; Jackson, G; Lawes, CM; Marshall, R; Thornley, S; Young, R	1
Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J	1
Takagi, H; Umemoto, T	1
Choudhury, RP; Iacob, AO	1
Araki, A; Iimuro, S; Ito, H; Matsuyama, Y; Ohashi, Y; Sakurai, T; Shinozaki, T; Umegaki, H	1
Buhre, WF; van Klei, WA	1
Beattie, WS; Fleisher, LA	1
Bragagnolo, JC; Catalano, H; Comignani, PD; Cornejo Pucci, E; Herrera, L; Igarzabal, C; Laffaye, N; Macchia, A; Mariani, JA; Nicolucci, A; Scazziota, AS; Tognoni, G	1
Hong, T; Huo, Y; Jia, J; Jiang, J; Li, J; Liu, P; Yu, R; Zhang, Y	1
Bryson, GL; Neilipovitz, DT; Taljaard, M	1
Betteridge, J; DeMicco, DA; Fayyad, R; Holme, I; Kvien, TK; LaRosa, JC; Pedersen, TR; Semb, AG; Wun, CC	1
Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M	1
Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A	1
Elis, A; Lishner, M	1
Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K	1
Gogolashvili, NG	1
Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A	1
Bittner, V; DeMicco, DA; LaRosa, JC; Messig, M; Waters, DD; Wenger, NK	1
Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD	1
Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A	1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J	1
Gropp, C	1
Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H	1
Velussi, M	1
Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J	1
Ostroumova, OD	1
Coupal, L; Grover, SA; Ho, V; Lavoie, F; Pilote, L; Zowall, H	1
Athyros, VG; Boudoulas, H; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN	1
Hennekens, CH; Serebruany, VL; Steinhubl, SR	1
Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA	1
Devroey, D; Ginst, LV	1
Ravnskov, U	1
Killestein, J	1
Trewby, P	1
Drummond, GA	1
Hackam, DG	1
De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA	1
García-Idoate, G; Mora, C; Muros, M; Navarro, JF	1
Bernaud, C; Boutouyrie, P; Christin-Maitre, S; Gompel, A; Jaillon, P; Laurent, S; Simon, T; Thuillez, C; Zannad, F	1
Ruef, J	1
Chimienti, S; Cristofano, C; Muscogiuri, P; Vernaglione, L	1
März, W	1
Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM	1
Topol, EJ	1
Fang, CH; Li, JJ	1
Hennekens, CH; Novela, C	1
Caramelli, B; De Bernoche, C; Durazzo, AE; Ikeoka, DT; Machado, FS; Monachini, MC; Puech-Leão, P	1
Economidou, O; Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K	1
Baumeister, B; Berthold, HK; Degenhardt, R; Gouni-Berthold, I; Krone, W; Unverdorben, M; Unverdorben, S; Vetter, H; Zittermann, A	1
Hamsten, A; Klareskog, L	1
Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O	1
Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R	1
Bates, ER; Carville, DG; Lau, WC	1
Hegmann, T	1
LeLorier, J; Paradis, JM	1
Gotto, AM	1
Miller, M	1
Philips, JC; Radermecker, RP; Scheen, AJ	1
Frishman, WH; Zuckerman, AL	1
März, W; Regourd, E; Ruf, G; Vetter, S	1
Bláha, V; Haas, T; Hyspler, R; Smahelová, A; Tichá, A; Zadák, Z	1
Bern, VH	1
Croom, KF; Plosker, GL	1
Baghestanian, M; Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S	1
Jacobs, PL; Johnson, BM; Nash, MS	1
Hirsch, M; Jones, P; O'Donnell, JC	1
Pitt, B	1
Barter, P; Fruchart, JC; Gotto, AM; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Shear, C; Shepherd, J; Waters, DD; Wenger, NK	1
Eisenbarth, GS	1
Bates, ER; Lau, WC	1
McFarlane, SI; Murad, O; Palmer, J; Sowers, J	1
Cannon, CP; Ray, KK	1
Kastelein, JJ; van Leuven, SI	1
Cowie, MR	1
Auer, J; Eber, B; Lamm, G	1
Southern, W	1
Braunwald, E; Cannon, CP; Murphy, SA	1
Ravnskov, U; Rosch, PJ; Sutter, MC	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Smulders, YM	1
Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S	1
Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K; Zisaki, K	1
Field, KM	1
Tseng, KH	1
Langmann, T; Schmitz, G	1
Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT	1
Bays, HE; Davidson, MH; McKenney, JM; Saponaro, J; Thompson, PD	1
Biccard, BM; Foëx, P; Sear, JW	1
Langer, A	1
Robinson, JG	1
Jaber, BL; Madias, NE	1
Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Thomason, MJ	1
Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J	1
Cannon, CP	1
Brännström, M; Bucht, B; Crougneau, V; Dimeny, E; Ekspong, A; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Welin, D; Wikdahl, AM	1
Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH	1
Frick, B; Fuchs, D; Schroecksnadel, K; Weiss, G; Winkler, C; Wirleitner, B	1
Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M	1
Mason, RP	2
Pilote, L; Rahme, E; Zhou, Z	1
Clearfield, M	1
Baheti, NN; Kulkarni, PM; Panchal, NV; Parale, GP	1
Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC	1
Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V	1
Rosenson, RS	1
Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD	1
Antoniades, C; Stefanadis, C; Tousoulis, D	1
Charlton-Menys, V; Durrington, P	1
Berneis, K; Rizzo, M	1
d'Emden, M; Knopp, RH; Pocock, SJ; Smilde, JG	1
Plummer, CJ	1
Babapulle, MN; Brophy, JM; Costa, V; Rinfret, S	1
Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA	1
Armani, A; Toth, PP	1
Davidson, MH; Robinson, JG	1
Beddhu, S; Cheung, AK; Kronenberg, F; Kwan, BC	1
Kiberd, BA	1
Palacios Muñoz, R; Santos González, J	1
Barter, P; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, SM; Haffner, S; Kastelein, JJ; LaRosa, JC; Schachner, H; Shepherd, J; Waters, DD	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Hérnandez, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P	1
Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A	1
Cohen, JS	1
East, JE	1
Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R	1
Tall, AR; Wang, N; Yvan-Charvet, L	1
Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; McGuire, A; Neil, HA; Raikou, M	1
Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y	1
Graff, J; Jönsson, B; Lindgren, P; Olsson, AG; Pedersen, TJ	1
Heering, NJ	1
Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM	1
Gorbas', IM; Iakimishina, LI; Kaĭdashev, IP; Petrushov, AV; Rasin, AM; Rasin, MS; Smirnova, IP; Vasil'ev, VN	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P	1
Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ	1
Bittner, V; Herrington, DM; Lewis, SJ; Welty, FK; Wenger, NK	2
McClendon, KS; Riche, DM	1
Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ	1
Asher, J; Houston, M	1
Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A	1
Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Pirpasopoulou, A; Skaperdas, A; Tziomalos, K	1
Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC	1
Mocanu, MM; Shakkottai, P; Yellon, DM	1
Frøbert, O; Holmager, P; Jensen, KM; Schmidt, EB; Simonsen, U	1
Benatar, JR; Stewart, RA	1
Emanuele, E; Geroldi, D	1
Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M	1
Poli, A	1
Arca, M	1
Arca, M; Gaspardone, A	1
Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD	1
Hirata, MH; Hirata, RD; Rodrigues, AC	1
Lyseng-Williamson, KA; Plosker, GL	1
Ghattas, AE; Pimenta, J	1
Hobbs, FD	1
Brännström, M; Bucht, S; Crougneau, V; Dimeny, E; Ekspong, A; Eriksson, M; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Stenlund, H; Wikdahl, AM	1
Bright, J	1
Levy, Y	1
Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR	1
Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM	1
Amann-Vesti, B; Brockes, C; Koppensteiner, R; Kovacevic, T; Rousson, V; Simon, R; Spring, S; van der Loo, B	1
Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ	1
Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM	1
De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C	1
Mascitelli, L; Vos, E	1
Alter, RA	1
Goldstein, MR	1
McKeage, K; Siddiqui, MA	1
Karam, JG; Loney-Hutchinson, L; McFarlane, SI	1
Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP	1
Bybee, KA; Lee, JH; O'Keefe, JH	1
Clarke, LD; Johnson, SJ; Liu, LZ; Ramsey, SD; Roberts, CS; Sullivan, SD	1
Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Gómez-Guerrero, C; Langer, A; Leiter, LA; Martín-Ventura, JL; Masramon, X	1
Doggrell, SA	2
Cohn, LJ	1
Farnier, M	1
Jones, PH	1
Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R	1
Angus, C; Genest, J; McPherson, R; Murray, P	1
Kluft, C	1

Reviews

85 review(s) available for atorvastatin and Cardiovascular Diseases

Article	Year
Synergistic actions between angiotensin-converting enzyme inhibitors and statins in atherosclerosis. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2022, Volume: 32, Issue:4 Topics: Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Renin-Angiotensin System	2022
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin. Current reviews in clinical and experimental pharmacology, 2023, Volume: 18, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin	2023
Pravastatin for lowering lipids. The Cochrane database of systematic reviews, 2023, 09-18, Volume: 9 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug-Related Side Effects and Adverse Reactions; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Pravastatin; Rosuvastatin Calcium	2023
[Efficacy and safety of atorvastatin in major cardiovascular events: Meta-analysis]. Revista medica del Instituto Mexicano del Seguro Social, 2023, Oct-02, Volume: 61, Issue:Suppl 3 Topics: Atorvastatin; Cardiovascular Diseases; Humans	2023
Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis. The Journal of international medical research, 2020, Volume: 48, Issue:6 Topics: Age Factors; Aged; Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Mortality; Primary Prevention; Randomized Controlled Trials as Topic; Secondary Prevention; Treatment Outcome	2020
Pitavastatin for lowering lipids. The Cochrane database of systematic reviews, 2020, 06-19, Volume: 6 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Controlled Before-After Studies; Drug Administration Schedule; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sex Factors; Triglycerides	2020
Comparative Effect of Statins and Omega-3 Supplementation on Cardiovascular Events: Meta-Analysis and Network Meta-Analysis of 63 Randomized Controlled Trials Including 264,516 Participants. Nutrients, 2020, Jul-25, Volume: 12, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Dietary Supplements; Fatty Acids, Omega-3; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Network Meta-Analysis; Pravastatin; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome	2020
Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient: A case report and literature review. Medicine, 2020, Oct-02, Volume: 99, Issue:40 Topics: Alanine Transaminase; Alkaline Phosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; gamma-Glutamyltransferase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Quinolines; Withholding Treatment	2020
Efficacy of high-dose atorvastatin or rosuvastatin loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials with GRADE qualification of available evidence. European journal of clinical pharmacology, 2022, Volume: 78, Issue:1 Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Randomized Controlled Trials as Topic; Rosuvastatin Calcium	2022
[Lipertance® The ASCOT single-pill combination has finally arrived]. Revue medicale de Liege, 2017, Volume: 72, Issue:9 Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Humans; Hypertension; Perindopril; Risk Factors	2017
Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology, 2018, Volume: 140, Issue:1 Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Primary Prevention; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium	2018
Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk. Atherosclerosis, 2018, Volume: 278 Topics: Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cholesterol, LDL; Europe; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Oxazolidinones; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; United Kingdom; United States	2018
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert opinion on pharmacotherapy, 2019, Volume: 20, Issue:8 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Risk Factors; Simvastatin	2019
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery. The Cochrane database of systematic reviews, 2013, Jul-03, Issue:7 Topics: Adult; Angioplasty; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Perioperative Care; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Sitosterols; Vascular Surgical Procedures	2013
Do statins play a role in renoprotection? Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic	2014
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. The American journal of cardiology, 2014, Jun-15, Volume: 113, Issue:12 Topics: Acute Kidney Injury; Aged; Atorvastatin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Survival Analysis	2014
Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients. Chinese medical journal, 2015, Jan-20, Volume: 128, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; China; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2015
[Choosing wisely when prescribing statins]. Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159 Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2015
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:10 Topics: Acute Kidney Injury; Atorvastatin; Cardiovascular Diseases; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Renal Insufficiency, Chronic; Risk; Rosuvastatin Calcium; Simvastatin	2015
To what extent do high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis. Atherosclerosis, 2015, Volume: 241, Issue:2 Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Male; Middle Aged; Odds Ratio; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Young Adult	2015
Meta-Analysis Comparing Rosuvastatin and Atorvastatin in Reducing Concentration of C-Reactive Protein in Patients With Hyperlipidemia. Angiology, 2016, Volume: 67, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Time Factors; Treatment Outcome	2016
The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thrombosis and haemostasis, 2016, Volume: 115, Issue:3 Topics: Adult; Aged; Antigens; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Thrombosis; von Willebrand Factor; Young Adult	2016
Improving cardiovascular protection: focus on a cardiovascular polypill. Future cardiology, 2016, Volume: 12, Issue:2 Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Platelet Aggregation Inhibitors; Ramipril; Simvastatin	2016
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention. International journal of cardiology, 2015, Volume: 201 Suppl 1 Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ramipril; Secondary Prevention	2015
Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants. Drug safety, 2016, Volume: 39, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Humans; Randomized Controlled Trials as Topic; Risk	2016
Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:4 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Combined Modality Therapy; Humans; Perindopril; Risk Factors	2016
Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis, 2016, Volume: 253 Topics: Adiponectin; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Quinolines; Randomized Controlled Trials as Topic; Regression Analysis; Rosuvastatin Calcium; Simvastatin	2016
Fibrates for primary prevention of cardiovascular disease events. The Cochrane database of systematic reviews, 2016, 11-16, Volume: 11 Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Middle Aged; Myocardial Infarction; Primary Prevention; Simvastatin; Stroke	2016
Statins and congestive heart failure. Current atherosclerosis reports, 2008, Volume: 10, Issue:5 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome	2008
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
Relative safety profiles of high dose statin regimens. Vascular health and risk management, 2008, Volume: 4, Issue:3 Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin	2008
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. Journal of the American College of Cardiology, 2008, Nov-25, Volume: 52, Issue:22 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk	2008
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 2 Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2009
[Atorvastatin in primary prevention]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 2 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles	2009
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vascular health and risk management, 2009, Volume: 5, Issue:1 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome	2009
Reducing morbidity and mortality in high risk patients with statins. Vascular health and risk management, 2009, Volume: 5, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors	2009
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). The American journal of cardiology, 2010, Jan-01, Volume: 105, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2010
A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins. Basic & clinical pharmacology & toxicology, 2010, Volume: 106, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cardiovascular System; Genetic Markers; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pyrroles; Up-Regulation	2010
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert review of cardiovascular therapy, 2010, Volume: 8, Issue:6 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles	2010
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers. Critical pathways in cardiology, 2010, Volume: 9, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States	2010
Pitavastatin: an overview. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL	2011
Pitavastatin: clinical effects from the LIVES Study. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides	2011
Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. International journal of cardiology, 2012, May-31, Volume: 157, Issue:2 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid	2012
Targeting HDL-cholesterol to reduce residual cardiovascular risk. Current opinion in lipidology, 2012, Volume: 23, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2012
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:6 Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis. International journal of cardiology, 2013, Sep-10, Volume: 167, Issue:6 Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2013
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2012, Volume: 22, Issue:9 Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult	2012
Non-every day statin administration--a literature review. European journal of internal medicine, 2012, Volume: 23, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2012
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine]. Kardiologiia, 2012, Volume: 52, Issue:7 Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency	2012
[Interactions of statins with antithrombotic drugs]. Medizinische Klinik (Munich, Germany : 1983), 2004, Feb-15, Volume: 99, Issue:2 Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors	2004
Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease. Journal of cardiovascular pharmacology and therapeutics, 2004, Volume: 9, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Lipid Peroxidation; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Ticlopidine	2004
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert review of cardiovascular therapy, 2004, Volume: 2, Issue:5 Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2004
The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients. International journal of clinical pharmacology and therapeutics, 2004, Volume: 42, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Drug Utilization Review; Germany; Heptanoic Acids; Humans; Lipids; Prospective Studies; Pyrroles	2004
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs, 2005, Volume: 65, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles	2005
Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Current diabetes reports, 2005, Volume: 5, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis	2005
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:6 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles	2005
Atorvastatin. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic	2005
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. International journal of clinical practice, 2005, Volume: 59, Issue:7 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome	2005
[Statins: for the time being, do not as a rule prescribe the maximum dose]. Nederlands tijdschrift voor geneeskunde, 2005, Aug-20, Volume: 149, Issue:34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles	2005
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels. Pharmacotherapy, 2005, Volume: 25, Issue:10 Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2005
High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy. Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:9 Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cardiovascular Diseases; DNA-Binding Proteins; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Intestinal Mucosa; Kidney; Lipid Metabolism; Lipoproteins, HDL; Liver X Receptors; Macrophages; Niacin; Orphan Nuclear Receptors; Pyrroles; Receptors, Cytoplasmic and Nuclear	2005
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American heart journal, 2006, Volume: 151, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome	2006
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:2 Pt 1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors	2006
Apolipoproteins AI and B as therapeutic targets. Journal of internal medicine, 2006, Volume: 259, Issue:5 Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles	2006
The clinical relevance of low-density-lipoproteins size modulation by statins. Cardiovascular drugs and therapy, 2006, Volume: 20, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
What's in the CARDS? Diabetic medicine : a journal of the British Diabetic Association, 2006, Volume: 23, Issue:7 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking	2006
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin	2006
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2007, Aug-01, Volume: 64, Issue:15 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic	2007
Statins and C-reactive protein levels. Journal of clinical hypertension (Greenwich, Conn.), 2007, Volume: 9, Issue:8 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles; Risk Factors	2007
The power of drug co-administration: smaller doses better outcomes. Cardiovascular drugs and therapy, 2007, Volume: 21, Issue:5 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Tetrazoles; Treatment Outcome	2007
Is it time to stop treating dyslipidaemia with fibrates? The New Zealand medical journal, 2007, Sep-07, Volume: 120, Issue:1261 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic	2007
Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2007
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke	2007
Atorvastatin: its clinical role in cerebrovascular prevention. Drugs, 2007, Volume: 67 Suppl 1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke	2007
The genetic determinants of atorvastatin response. Current opinion in molecular therapeutics, 2007, Volume: 9, Issue:6 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors	2007
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events. PharmacoEconomics, 2007, Volume: 25, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2007
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vascular health and risk management, 2007, Volume: 3, Issue:5 Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Guidelines as Topic; Heptanoic Acids; Humans; Pyrroles; Risk Factors	2007
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia. Current diabetes reviews, 2005, Volume: 1, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States	2005
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics	2008
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2008, Volume: 8, Issue:1 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles	2008
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current medical research and opinion, 2008, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke	2008
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management. Drugs, 2008, Volume: 68, Issue:7 Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2008
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
[The hyperlipidemias. Role of various statins]. Presse medicale (Paris, France : 1983), 1999, Nov-20, Volume: 28, Issue:36 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin	1999

Trials

148 trial(s) available for atorvastatin and Cardiovascular Diseases

Article	Year
Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. European journal of clinical pharmacology, 2022, Volume: 78, Issue:3 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Disabled Persons; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Primary Prevention; Proportional Hazards Models; Rosuvastatin Calcium; Simvastatin	2022
High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study. European journal of preventive cardiology, 2022, 10-18, Volume: 29, Issue:13 Topics: Atorvastatin; Cardiovascular Diseases; Cholestanol; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Sterols	2022
Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. Journal of hypertension, 2022, 08-01, Volume: 40, Issue:8 Topics: Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Endothelial Cells; Extracellular Vesicles; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Risk Factors	2022
Polypill Strategy in Secondary Cardiovascular Prevention. The New England journal of medicine, 2022, 09-15, Volume: 387, Issue:11 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Myocardial Infarction; Platelet Aggregation Inhibitors; Ramipril; Secondary Prevention	2022
An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV. AIDS (London, England), 2023, 10-01, Volume: 37, Issue:12 Topics: Anti-Retroviral Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Inflammation; Male; Middle Aged; Viral Load	2023
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet (London, England), 2019, 08-24, Volume: 394, Issue:10199 Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan	2019
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents? Revista espanola de cardiologia (English ed.), 2021, Volume: 74, Issue:1 Topics: Aspirin; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ramipril; Treatment Outcome	2021
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. International journal of cardiology, 2020, 04-15, Volume: 305 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome	2020
Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial. Archives of Iranian medicine, 2020, 08-01, Volume: 23, Issue:8 Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Humans; Hydrochlorothiazide; Iran; Male; Middle Aged; Pragmatic Clinical Trials as Topic	2020
CAVI-Lowering Effect of Pitavastatin May Be Involved in the Prevention of Cardiovascular Disease: Subgroup Analysis of the TOHO-LIP. Journal of atherosclerosis and thrombosis, 2021, Oct-01, Volume: 28, Issue:10 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardio Ankle Vascular Index; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines	2021
A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis. European journal of preventive cardiology, 2021, 07-23, Volume: 28, Issue:8 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Renal Dialysis	2021
Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability. Drug design, development and therapy, 2017, Volume: 11 Topics: Administration, Oral; Adolescent; Adult; Amlodipine; Atorvastatin; Biological Availability; Caco-2 Cells; Cardiovascular Diseases; Cells, Cultured; Dose-Response Relationship, Drug; Drug Compounding; Female; Healthy Volunteers; Humans; Male; Middle Aged; Models, Biological; Reproducibility of Results; Tablets; Young Adult	2017
Body-Weight Fluctuations and Outcomes in Coronary Disease. The New England journal of medicine, 2017, 04-06, Volume: 376, Issue:14 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Risk Factors; Weight Gain; Weight Loss	2017
Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clinical drug investigation, 2017, Volume: 37, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Psoriasis	2017
Long-term Effects of high-doSe pitavaStatin on Diabetogenicity in comparison with atorvastatin in patients with Metabolic syndrome (LESS-DM): study protocol for a randomized controlled trial. Trials, 2017, Oct-27, Volume: 18, Issue:1 Topics: Atorvastatin; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Clinical Protocols; Diabetes Mellitus; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Metabolic Syndrome; Prospective Studies; Quinolines; Republic of Korea; Research Design; Risk Factors; Time Factors; Treatment Outcome	2017
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. JAMA cardiology, 2017, 12-01, Volume: 2, Issue:12 Topics: Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Patient Care Planning; PCSK9 Inhibitors; Rosuvastatin Calcium; Stroke; Treatment Outcome	2017
Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ open, 2017, Dec-01, Volume: 7, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Primary Health Care; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom	2017
Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. JAMA, 2018, 04-03, Volume: 319, Issue:13 Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Preoperative Care; ST Elevation Myocardial Infarction	2018
A Rapid (Differential) Effect of Rosuvastatin and Atorvastatin on High-Sensitivity Cardiac Troponin-I in Subjects With Stable Cardiovascular Disease. Clinical pharmacology and therapeutics, 2018, Volume: 104, Issue:2 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Down-Regulation; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Prospective Studies; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Troponin I	2018
Development, validation and application of a novel HPLC-MS/MS method for the quantification of atorvastatin, bisoprolol and clopidogrel in a large cardiovascular patient cohort. Journal of pharmaceutical and biomedical analysis, 2018, Sep-10, Volume: 159 Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Bisoprolol; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Clopidogrel; Cohort Studies; Female; Humans; Male; Mass Spectrometry; Platelet Aggregation Inhibitors; Prospective Studies; Reproducibility of Results; Tandem Mass Spectrometry; Ticlopidine	2018
Different Effects of Atorvastatin on Cardiometabolic Risk Factors in Young Women With and Without Hyperprolactinemia. Journal of clinical pharmacology, 2019, Volume: 59, Issue:1 Topics: Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperprolactinemia; Lipids; Metabolic Diseases; Middle Aged; Prolactin; Risk Factors	2019
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet (London, England), 2018, 09-29, Volume: 392, Issue:10153 Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Risk Factors; United Kingdom	2018
High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the Treating to New Targets [TNT] Study). Metabolism: clinical and experimental, 2019, Volume: 93 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Coronary Artery Disease; Female; Fibroblast Growth Factors; Humans; Male; Middle Aged; Predictive Value of Tests	2019
A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:9 Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Humans; Male; Middle Aged; Primary Prevention; Proportional Hazards Models; Treatment Outcome	2019
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:1 Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2014
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Life sciences, 2013, May-02, Volume: 92, Issue:14-16 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric	2013
[Prevention of cardiovascular complications in patients undergoing aortic-iliac reconstructions by correction of inflammation and endotoxemia]. Vestnik Rossiiskoi akademii meditsinskikh nauk, 2013, Issue:2 Topics: Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endotoxemia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome; Vascular Surgical Procedures	2013
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm. Journal of the American College of Cardiology, 2013, Aug-20, Volume: 62, Issue:8 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Treatment Outcome	2013
No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease. The Netherlands journal of medicine, 2013, Volume: 71, Issue:7 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Deoxyguanosine; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Pyrroles; Simvastatin; Ubiquinone	2013
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial. Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:2 Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine	2014
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research, 2014, Volume: 11, Issue:1 Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors	2014
Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study. Journal of cardiology, 2014, Volume: 63, Issue:5 Topics: Acute Coronary Syndrome; Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Complications; Preoperative Care; Pyrroles; Time Factors; Ultrasonography	2014
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scandinavian journal of clinical and laboratory investigation, 2014, Volume: 74, Issue:4 Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell biochemistry and biophysics, 2014, Volume: 70, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cell-Derived Microparticles; Cholesterol, LDL; Drug Interactions; Endothelial Progenitor Cells; Ezetimibe; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Risk	2014
[Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk]. Kardiologiia, 2014, Volume: 54, Issue:2 Topics: Adult; Androgens; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Erectile Dysfunction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Penile Erection; Pyrroles; Risk Factors	2014
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients. Atherosclerosis, 2014, Volume: 236, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult	2014
Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin. Journal of pediatric endocrinology & metabolism : JPEM, 2015, Volume: 28, Issue:1-2 Topics: Adolescent; Anticholesteremic Agents; Arginine; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Homoarginine; Humans; Lipids; Male; Pilot Projects; Pyrroles; Risk Factors; Treatment Outcome	2015
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial. European journal of preventive cardiology, 2015, Volume: 22, Issue:12 Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan	2015
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies Clinical cardiology, 2014, Volume: 37, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2014
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction – ALPS-AMI study. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydrophobic and Hydrophilic Interactions; Hypercholesterolemia; Japan; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Patient Acceptance of Health Care; Pravastatin; Recurrence; Single-Blind Method; Solubility	2015
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. Journal of the American College of Cardiology, 2015, Apr-07, Volume: 65, Issue:13 Topics: Aged; Apolipoprotein B-100; Atorvastatin; Biomarkers; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Risk Factors	2015
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial. Diabetologia, 2015, Volume: 58, Issue:7 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged	2015
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. Journal of the American College of Cardiology, 2015, Jun-02, Volume: 65, Issue:21 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholestanol; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis	2015
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:8 Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome	2015
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia. Cardiovascular therapeutics, 2015, Volume: 33, Issue:5 Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid	2015
PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol. Archives of Iranian medicine, 2015, Volume: 18, Issue:8 Topics: Angiotensin II Type 1 Receptor Blockers; Aspirin; Atorvastatin; Cardiovascular Diseases; Diuretics; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Platelet Aggregation Inhibitors; Urban Population; Valsartan	2015
Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Fasting; Female; Humans; Hypertension; Male; Metabolic Syndrome; Middle Aged; Predictive Value of Tests; Risk Factors; Triglycerides	2016
Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2016, Volume: 31, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoprotein(a); Atorvastatin; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lipoprotein(a); Male; Middle Aged; Phenotype; Prospective Studies; Protein Isoforms; Renal Dialysis; Survival Rate; Time Factors; Young Adult	2016
Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney international, 2016, Volume: 89, Issue:6 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Assessment; Surveys and Questionnaires; Time Factors	2016
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis, 2016, Volume: 254 Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Simvastatin; Treatment Outcome	2016
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States	2008
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). Journal of human hypertension, 2009, Volume: 23, Issue:3 Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome	2009
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. Orvosi hetilap, 2008, Sep-28, Volume: 149, Issue:39 Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors	2008
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diabetes & vascular disease research, 2008, Volume: 5, Issue:4 Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Microcirculation; Middle Aged; Pioglitazone; Prospective Studies; Pyrroles; Radial Artery; Risk Assessment; Skin; Thiazolidinediones; Treatment Outcome; Ultrasonography	2008
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis, 2009, Volume: 204, Issue:2 Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides	2009
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2009, Volume: 52, Issue:2 Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides	2009
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study) The American journal of cardiology, 2008, Nov-15, Volume: 102, Issue:10 Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reoperation	2008
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia, 2009, Volume: 52, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles	2009
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clinical journal of the American Society of Nephrology : CJASN, 2009, Volume: 4, Issue:2 Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2009
Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction. Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:5 Topics: Aged; Atorvastatin; Biomarkers; Biopterins; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Risk Assessment; Risk Factors; Ultrasonography; Vasodilation	2009
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2009, Volume: 16, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome	2009
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:5 Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles	2009
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension (Dallas, Tex. : 1979), 2009, Volume: 54, Issue:4 Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors	2009
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 54, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis	2009
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis, 2010, Volume: 209, Issue:1 Topics: Atorvastatin; Blood Vessels; Cardiovascular Diseases; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles	2010
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial. The Canadian journal of cardiology, 2009, Volume: 25, Issue:11 Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome	2009
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I Journal of the American College of Cardiology, 2009, Dec-08, Volume: 54, Issue:24 Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles	2009
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clinical therapeutics, 2009, Volume: 31, Issue:12 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tablets; Time Factors; Treatment Outcome; Triglycerides; United States	2009
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circulation. Cardiovascular genetics, 2010, Volume: 3, Issue:2 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Chromosomes, Human, Pair 3; Female; Gene Deletion; Gene Frequency; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR; Receptors, CCR5; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides	2010
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial. Journal of internal medicine, 2010, Volume: 267, Issue:6 Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin	2010
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. Postgraduate medicine, 2010, Volume: 122, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires	2010
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg. Cardiovascular drugs and therapy, 2010, Volume: 24, Issue:2 Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Epidemiologic Research Design; Female; Heptanoic Acids; Humans; Interleukin-6; Korea; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Young Adult	2010
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. International journal of clinical practice, 2010, Volume: 64, Issue:8 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome	2010
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial. International journal of clinical practice, 2010, Volume: 64, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors	2010
[A comparative study of the efficacy and safety Zhibitai and atorvastatin]. Zhonghua nei ke za zhi, 2010, Volume: 49, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles	2010
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. International journal of clinical practice, 2010, Volume: 64, Issue:9 Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets	2010
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study. Atherosclerosis, 2010, Volume: 212, Issue:1 Topics: Acute Coronary Syndrome; Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Up-Regulation	2010
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clinical therapeutics, 2010, Volume: 32, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Therapeutic Equivalency; Treatment Outcome; Young Adult	2010
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 2011, Volume: 28, Issue:7 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome	2011
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. Journal of hypertension, 2011, Volume: 29, Issue:3 Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Pyrroles	2011
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Current medical research and opinion, 2011, Volume: 27, Issue:4 Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care	2011
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. Current vascular pharmacology, 2011, Volume: 9, Issue:6 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors	2011
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clinical journal of the American Society of Nephrology : CJASN, 2011, Volume: 6, Issue:6 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2011
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR American heart journal, 2011, Volume: 161, Issue:6 Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment	2011
Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:8 Topics: Aged; Aged, 80 and over; Angioplasty; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Postoperative Complications; Pyrroles; Quinolines; Retrospective Studies; Risk Factors	2011
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Current medical research and opinion, 2011, Volume: 27, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Uric Acid	2011
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study. Atherosclerosis, 2011, Volume: 219, Issue:2 Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome	2011
Short-term effect of atorvastatin on carotid artery elasticity: a pilot study. Stroke, 2011, Volume: 42, Issue:12 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Treatment Outcome; Ultrasonography	2011
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology, 2012, Volume: 63, Issue:5 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Time Factors; Treatment Outcome	2012
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA, 2011, Nov-16, Volume: 306, Issue:19 Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2011
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circulation. Cardiovascular genetics, 2012, Feb-01, Volume: 5, Issue:1 Topics: Aged; Alleles; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome	2012
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids in health and disease, 2012, Jan-31, Volume: 11 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2012
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial. PloS one, 2012, Volume: 7, Issue:3 Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Thrombin	2012
Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2012, May-01, Volume: 79, Issue:6 Topics: Angioplasty, Balloon, Coronary; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; China; Coronary Artery Disease; Creatine; Creatine Kinase, MB Form; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Time Factors; Treatment Outcome; Troponin I	2012
STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2012, Volume: 59, Issue:6 Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyrroles; Risk Factors; Surgical Procedures, Operative	2012
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis and rheumatism, 2012, Volume: 64, Issue:9 Topics: Adult; Aged; Anticholesteremic Agents; Arthritis; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome	2012
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease. American heart journal, 2012, Volume: 164, Issue:3 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Risk Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency	2012
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Journal of the American College of Cardiology, 2013, Jan-15, Volume: 61, Issue:2 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke	2013
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diabetes & vascular disease research, 2013, Volume: 10, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides	2013
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis, 2002, Volume: 164, Issue:2 Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome	2002
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Current medical research and opinion, 2003, Volume: 19, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Cardiovascular Diseases; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Time; United States	2003
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus. Journal of thrombosis and haemostasis : JTH, 2003, Volume: 1, Issue:8 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor	2003
Rationale, design and methods of the CASHMERE study. Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:1 Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Endpoint Determination; Estrogen Replacement Therapy; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Prospective Studies; Pyrroles; Research Design; Treatment Outcome	2004
Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis? American journal of kidney diseases : the official journal of the National Kidney Foundation, 2004, Volume: 43, Issue:3 Topics: Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis	2004
[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study]. Der Internist, 2004, Volume: 45, Issue:3 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles	2004
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of vascular surgery, 2004, Volume: 39, Issue:5 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Patient Compliance; Postoperative Complications; Prospective Studies; Pyrroles; Risk Factors; Time Factors; Vascular Surgical Procedures	2004
Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2004, Volume: 24, Issue:4 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Triglycerides	2004
Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2004, Volume: 15, Issue:6 Topics: Aged; Aging; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cardiovascular Diseases; Collagen; Collagen Type I; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Osteocalcin; Peptides; Postmenopause; Prospective Studies; Pyrroles; Risk Factors	2004
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor	2004
Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial. Clinical chemistry, 2005, Volume: 51, Issue:1 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Skin	2005
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, 2005, Volume: 12, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2005
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine, 2005, Apr-07, Volume: 352, Issue:14 Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides	2005
Statin treatment of patients with diabetes. Current diabetes reports, 2005, Volume: 5, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2005
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. Journal of cardiovascular pharmacology, 2005, Volume: 46, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors	2005
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2005, Volume: 48, Issue:12 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Proportional Hazards Models; Pyrroles; Risk Factors; Time Factors; Treatment Outcome	2005
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA, 2005, Nov-16, Volume: 294, Issue:19 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin	2005
Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scandinavian journal of urology and nephrology, 2005, Volume: 39, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Triglycerides	2005
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Current medical research and opinion, 2005, Volume: 21, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome	2005
Effects of atorvastatin on higher functions. European journal of clinical pharmacology, 2006, Volume: 62, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Cognition; Female; Heptanoic Acids; Humans; Intelligence Tests; Male; Mental Processes; Middle Aged; Pyrroles; Treatment Outcome	2006
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. The American journal of cardiology, 2006, Mar-01, Volume: 97, Issue:5 Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents	2006
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal]. Revue medicale de Liege, 2006, Volume: 61, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome	2006
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes care, 2006, Volume: 29, Issue:7 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome	2006
High-dose atorvastatin after stroke or transient ischemic attack. The New England journal of medicine, 2006, 08-10, Volume: 355, Issue:6 Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke	2006
The CARDS trial: diabetic patients dealt a winning hand. Current atherosclerosis reports, 2006, Volume: 8, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome	2006
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors	2006
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST. Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors	2007
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. Journal of the American Society of Nephrology : JASN, 2006, Volume: 17, Issue:12 Suppl 3 Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator	2006
Effect of torcetrapib on the progression of coronary atherosclerosis. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional	2007
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. American heart journal, 2007, Volume: 153, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome	2007
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Annals of internal medicine, 2007, Jul-03, Volume: 147, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides	2007
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. Journal of the American College of Cardiology, 2007, Jul-24, Volume: 50, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine	2007
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Current medical research and opinion, 2007, Volume: 23, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2007
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). The American journal of cardiology, 2007, Sep-01, Volume: 100, Issue:5 Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome	2007
Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk. Scandinavian cardiovascular journal : SCJ, 2008, Volume: 42, Issue:1 Topics: Administration, Inhalation; Adult; Atorvastatin; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperoxia; Hypoxia; Lipoproteins; Male; Middle Aged; Nitroglycerin; Oxygen; Pyrroles; Regional Blood Flow; Research Design; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasoconstriction; Vasodilation; Vasodilator Agents	2008
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England journal of medicine, 2007, Sep-27, Volume: 357, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk	2007
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine, 2007, Nov-22, Volume: 357, Issue:21 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines	2007
Efficacy of atorvastatin when not administered daily. Arquivos brasileiros de cardiologia, 2007, Volume: 89, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides	2007
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study. Heart (British Cardiac Society), 2008, Volume: 94, Issue:4 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles; Sex Factors; Survival Analysis; Treatment Outcome; United States	2008
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study. Scandinavian journal of urology and nephrology, 2005, Volume: 39, Issue:6 Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Prospective Studies; Pyrroles	2005
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Current medical research and opinion, 2007, Volume: 23, Issue:12 Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2007
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome	2008
High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Aged; Ankle; Atorvastatin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Arteries; Disease Progression; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Prospective Studies; Pyrroles; Research Design; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation	2008
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. European journal of pharmacology, 2008, May-31, Volume: 586, Issue:1-3 Topics: Adiponectin; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides	2008
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2001, Volume: 16, Issue:1 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyridines; Pyrroles; Safety	2001
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholest American heart journal, 2001, Volume: 141, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Canada; Cardiovascular Diseases; Cholesterol, LDL; Female; Health Education; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Factors; Women's Health	2001

Other Studies

245 other study(ies) available for atorvastatin and Cardiovascular Diseases

Article	Year
Statins No Longer Contraindicated in Pregnancy. The American journal of nursing, 2021, 11-01, Volume: 121, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; Contraindications; Drug Approval; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pregnancy; United States; United States Food and Drug Administration	2021
Simvastatin is associated with superior lipid and glycaemic control to atorvastatin and reduced levels of incident Type 2 diabetes, in men and women, in the UK Biobank. Endocrinology, diabetes & metabolism, 2022, Volume: 5, Issue:3 Topics: Atorvastatin; Biological Specimen Banks; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Glycemic Control; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Simvastatin; United Kingdom	2022
Pleiotropic effects of pitavastatin: a pilot study using the saphenous vein endothelial cell model of endothelial injury and prevention of atherosclerosis. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:14 Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cytokines; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pilot Projects; Quinolines; Saphenous Vein; Tumor Necrosis Factor-alpha	2022
Seven days of statin treatment improves nitric-oxide mediated endothelial-dependent cutaneous microvascular function in women with endometriosis. Microvascular research, 2022, Volume: 144 Topics: Atorvastatin; Cardiovascular Diseases; Endometriosis; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microcirculation; Nitric Oxide; Regional Blood Flow; Skin; Vasodilation	2022
Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates. Human genomics, 2022, 09-25, Volume: 16, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Pharmacogenetics; Pilot Projects; Rosuvastatin Calcium; United Arab Emirates; Vitamin K Epoxide Reductases; Warfarin	2022
Cabergoline-Induced Hypoprolactinemia May Attenuate Cardiometabolic Effects of Atorvastatin: A Pilot Study. Cardiology, 2022, Volume: 147, Issue:5-6 Topics: Androgens; Atorvastatin; C-Reactive Protein; Cabergoline; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Insulin Resistance; Pilot Projects; Prolactin; Risk Factors; Uric Acid	2022
Detection of lipid efflux from foam cell models using a label-free infrared method. The Analyst, 2022, Nov-21, Volume: 147, Issue:23 Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol; Foam Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic	2022
[The atorvastatin effects on the prevention of contrast-induced acute kidney injury during computed tomography with contrast media]. Terapevticheskii arkhiv, 2022, Oct-24, Volume: 94, Issue:9 Topics: Acute Kidney Injury; Atorvastatin; Cardiovascular Diseases; Contrast Media; Creatinine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Risk Factors; Tomography, X-Ray Computed	2022
Fixed dose combination drugs for cardiovascular disease in a prolonged humanitarian crisis in Lebanon: an implementation study. BMJ open, 2023, 01-25, Volume: 13, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; COVID-19; Drug Combinations; Humans; Lebanon; Pandemics	2023
Cardiometabolic Risk Factors in Atorvastatin-Treated Women with Euthyroid Autoimmune Thyroiditis. Pharmacology, 2023, Volume: 108, Issue:3 Topics: Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Cholesterol; Female; Fibrinogen; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors; Thyroiditis, Autoimmune; Uric Acid	2023
[Lipid-lowering Eeficacy and Safety of High Doses of Atorvastatin and Rosuvastatin]. Kardiologiia, 2023, Feb-28, Volume: 63, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Retrospective Studies; Rosuvastatin Calcium; Triglycerides	2023
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study. European journal of clinical pharmacology, 2023, Volume: 79, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin	2023
The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan. European review for medical and pharmacological sciences, 2023, Volume: 27, Issue:12 Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jordan; Primary Prevention; United States	2023
The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome. Pharmacology, 2023, Volume: 108, Issue:5 Topics: Androgens; Atorvastatin; C-Reactive Protein; Cardiometabolic Risk Factors; Cardiovascular Diseases; Female; Fibrinogen; Humans; Insulin Resistance; Polycystic Ovary Syndrome; Risk Factors; Siblings; Testosterone; Uric Acid	2023
Impact of Macroprolactinemia on Cardiometabolic Effects of Atorvastatin in Women With Hypercholesterolemia. The American journal of cardiology, 2019, 10-15, Volume: 124, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Hyperprolactinemia; Incidence; Insulin Resistance; Middle Aged; Poland; Prolactin; Risk Factors	2019
Percentage low-density lipoprotein-cholesterol response to a given statin dose is not fixed across the pre-treatment range: Real world evidence from clinical practice: Data from the ESC-EORP EUROASPIRE V Study. European journal of preventive cardiology, 2020, Volume: 27, Issue:15 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Europe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Risk Factors; Rosuvastatin Calcium; Time Factors; Treatment Outcome; Young Adult	2020
Intensive Statin Therapy Compromises the Adiponectin-AdipoR Pathway in the Human Monocyte-Macrophage Lineage. Stroke, 2019, Volume: 50, Issue:12 Topics: Adiponectin; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Carotid Artery Diseases; Dose-Response Relationship, Drug; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Monocytes; Receptors, Adiponectin; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; THP-1 Cells; Tumor Necrosis Factor-alpha	2019
Method development for quantitative determination of seven statins including four active metabolites by means of high-resolution tandem mass spectrometry applicable for adherence testing and therapeutic drug monitoring. Clinical chemistry and laboratory medicine, 2020, 04-28, Volume: 58, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Drug Monitoring; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Lovastatin; Medication Adherence; Pravastatin; Quality Control; Reference Standards; Tandem Mass Spectrometry	2020
Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. Lipids in health and disease, 2019, Dec-11, Volume: 18, Issue:1 Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Recurrence; Registries; Retrospective Studies; Rosuvastatin Calcium; Secondary Prevention; Spain; Therapeutic Equivalency	2019
Overuse of Statins in Older Adults. American family physician, 2019, 12-15, Volume: 100, Issue:12 Topics: Accidental Falls; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Fractures, Bone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle Weakness; Patient Participation; Prescription Drug Overuse; Risk Factors	2019
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill. Vnitrni lekarstvi, 2020,Winter, Volume: 65, Issue:12 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Humans; Hypertension; Perindopril	2020
Aging does not impact drug--drug interaction magnitudes with antiretrovirals. AIDS (London, England), 2020, 05-01, Volume: 34, Issue:6 Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome	2020
Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI. JAMA, 2020, 02-25, Volume: 323, Issue:8 Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention	2020
Variability in blood lipids affects the neutrophil to lymphocyte ratio in patients undergoing elective percutaneous coronary intervention: a retrospective study. Lipids in health and disease, 2020, Jun-03, Volume: 19, Issue:1 Topics: Aged; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipid Metabolism; Lipids; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Risk Factors	2020
The particulars of certain drugs' effect on the endogenous coenzyme Q10 plasma level in patients with cardiovascular diseases. Drug metabolism and personalized therapy, 2020, 06-30, Volume: 35, Issue:2 Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Female; Humans; Male; Middle Aged; Tandem Mass Spectrometry; Ubiquinone	2020
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type. International journal of environmental research and public health, 2020, 08-30, Volume: 17, Issue:17 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin	2020
Euvascor - early intervention of hypertension and dyslipidaemia (dual combination of atorvastatin and perindopril). Vnitrni lekarstvi, 2020,Spring, Volume: 66, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Czech Republic; Dyslipidemias; Humans; Hypertension; Perindopril	2020
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins. BMC pharmacology & toxicology, 2021, 02-04, Volume: 22, Issue:1 Topics: Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Registries; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Treatment Outcome	2021
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management]. Revue medicale de Liege, 2021, Volume: 76, Issue:2 Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Heart Disease Risk Factors; Humans; Hypertension; Perindopril; Risk Factors	2021
Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease. Scientific reports, 2021, 02-18, Volume: 11, Issue:1 Topics: Aged; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Female; Fluorodeoxyglucose F18; Heart Disease Risk Factors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plaque, Atherosclerotic; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Renal Insufficiency, Chronic; Risk Factors	2021
Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease. Journal of atherosclerosis and thrombosis, 2022, 04-01, Volume: 29, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Pyrroles; Quinolines	2022
Mediational g-formula for time-varying treatment and repeated-measured multiple mediators: Application to atorvastatin's effect on cardiovascular disease via cholesterol lowering and anti-inflammatory actions in elderly type 2 diabetics. Statistical methods in medical research, 2021, Volume: 30, Issue:8 Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans	2021
Effects of atorvastatin doses on serum level of procalcitonin and predictors for major adverse cardiovascular events in patients with acute myocardial infarction: a pilot study and post hoc analysis. Coronary artery disease, 2022, 01-01, Volume: 31, Issue:1 Topics: Aged; Atorvastatin; Beijing; Biomarkers; Cardiovascular Diseases; Female; Humans; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Procalcitonin; Prognosis	2022
Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis. Journal of the American Heart Association, 2017, Apr-01, Volume: 6, Issue:4 Topics: Aged; Atorvastatin; Atrial Fibrillation; Black People; Cardiomyopathy, Dilated; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Artery Disease; Diabetes Mellitus; Fatty Acids, Monounsaturated; Fluvastatin; Ghana; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Kaplan-Meier Estimate; Longitudinal Studies; Middle Aged; Mortality; Multivariate Analysis; Probability; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Treatment Outcome	2017
10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. BMJ open, 2017, 05-17, Volume: 7, Issue:5 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Drug Utilization; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Taiwan	2017
LDL cholesterol levels after switch from atorvastatin to rosuvastatin. Current medical research and opinion, 2018, Volume: 34, Issue:10 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Monitoring; Drug Substitution; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; United States	2018
[Effects of High-Dose Statin Therapy on Cognitive Functions and Quality of Life in Very High Cardiovascular Risk Patients]. Kardiologiia, 2017, Volume: 57, Issue:9 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cognition; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quality of Life; Risk Factors; Russia	2017
Statin use in Brazil: findings and implications. Current medical research and opinion, 2018, Volume: 34, Issue:10 Topics: Adult; Aged; Atorvastatin; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Drug Utilization Review; Female; Health Equity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medication Adherence; Middle Aged; Primary Health Care; Rosuvastatin Calcium; Simvastatin	2018
[The REVEAL study]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:2 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxazolidinones; Randomized Controlled Trials as Topic; Treatment Outcome	2018
Effects of different statin types and dosages on systolic/diastolic blood pressure: Retrospective analysis of 24-hour ambulatory blood pressure database. Journal of clinical hypertension (Greenwich, Conn.), 2018, Volume: 20, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Cross-Sectional Studies; Diastole; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Systole	2018
Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg. Revista espanola de cardiologia (English ed.), 2018, Volume: 71, Issue:7 Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Consensus; Drug Combinations; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ramipril; Secondary Prevention	2018
Long-term atorvastatin treatment decreases heart maximal oxygen consumption and its vulnerability to in vitro oxidative stress in Watanabe heritable hyperlipidemic rabbit. Canadian journal of physiology and pharmacology, 2018, Volume: 96, Issue:11 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Disease Models, Animal; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mitochondria, Heart; Myocardium; Oxidative Stress; Oxygen Consumption; Rabbits; Reactive Oxygen Species; Time Factors	2018
The Relationship Between Statin Action On Thyroid Autoimmunity And Vitamin D Status: A Pilot Study. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2019, Volume: 127, Issue:1 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pilot Projects; Thyroid Function Tests; Thyroid Hormones; Thyrotropin; Vitamin D; Vitamin D Deficiency	2019
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease. BMJ (Clinical research ed.), 2018, Sep-20, Volume: 362 Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Gout; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Purinergic P2Y Receptor Antagonists; Risk Factors; Uric Acid	2018
Prediabetes with Hypertension and Dyslipidemia: Are They Triad of Future Cardiovascular Risk? Cardiovascular drugs and therapy, 2019, Volume: 33, Issue:6 Topics: Atorvastatin; Cardiovascular Diseases; China; Dyslipidemias; Glucose; Glycated Hemoglobin; Humans; Hypertension; Prediabetic State; Quinolines; Risk Factors	2019
Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia. Diabetes & vascular disease research, 2019, Volume: 16, Issue:1 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulse Wave Analysis; Risk Factors; Time Factors; Treatment Outcome; Vascular Stiffness	2019
Apelin‑13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high‑fat diet. Molecular medicine reports, 2018, Volume: 18, Issue:6 Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Heart Function Tests; Hemodynamics; Intercellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Metformin; Oxidation-Reduction; Protective Agents; Rats	2018
Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD. International heart journal, 2019, Jan-25, Volume: 60, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Computed Tomography Angiography; Coronary Artery Disease; Coronary Vessels; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome	2019
Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Annals of internal medicine, 2019, 01-01, Volume: 170, Issue:1 Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Primary Prevention; Risk Assessment; Rosuvastatin Calcium; Sex Factors; Simvastatin	2019
A Method for Direct Monitoring of Atorvastatin Adherence in Cardiovascular Disease Prevention: Quantification of the Total Exposure to Parent Drug and Major Metabolites Using 2-Channel Chromatography and Tandem Mass Spectrometry. Therapeutic drug monitoring, 2019, Volume: 41, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Blood Specimen Collection; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Pilot Projects; Reproducibility of Results; Tandem Mass Spectrometry	2019
Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use. Clinical pharmacology and therapeutics, 2019, Volume: 105, Issue:6 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Drugs, Generic; Electronic Health Records; Female; Humans; Male; Medicare; Middle Aged; Propensity Score; Social Class; United States	2019
Fibroblast growth factor 21: A role in cardiometabolic disorders and cardiovascular risk prediction? Metabolism: clinical and experimental, 2019, Volume: 93 Topics: Atorvastatin; Cardiovascular Diseases; Fibroblast Growth Factors; Humans; Risk Factors; Trinitrotoluene	2019
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. The American journal of cardiology, 2019, 04-15, Volume: 123, Issue:8 Topics: Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Retrospective Studies	2019
Comparative effectiveness of statins in secondary prevention among the older people aged 75 years and over. International journal of clinical pharmacy, 2019, Volume: 41, Issue:2 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance Benefits; Insurance, Health; Male; Protective Factors; Retrospective Studies; Rosuvastatin Calcium; Secondary Prevention	2019
Lipids and Cardiovascular Risk Through the Lens of Rheumatoid Arthritis. Arthritis & rheumatology (Hoboken, N.J.), 2019, Volume: 71, Issue:9 Topics: Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Humans; Lipids; Primary Prevention; Risk Factors	2019
The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacological reports : PR, 2019, Volume: 71, Issue:3 Topics: Adrenal Hyperplasia, Congenital; Adult; Androgens; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Female; Fibrinogen; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pilot Projects; Risk Factors; Testosterone; Uric Acid; Vitamin D	2019
Evacetrapib reduces preβ-1 HDL in patients with atherosclerotic cardiovascular disease or diabetes. Atherosclerosis, 2019, Volume: 285 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Diabetes Mellitus; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors	2019
Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC research notes, 2019, Jul-09, Volume: 12, Issue:1 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Ethiopia; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Retrospective Studies; Rosuvastatin Calcium; Simvastatin	2019
Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Experimental biology and medicine (Maywood, N.J.), 2013, Volume: 238, Issue:2 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Heptanoic Acids; Hypoxia; Oxidative Stress; Pyrroles; Rats; Treatment Outcome	2013
Factors associated with statin selection among privately insured commercial and Medicare patients. Current medical research and opinion, 2013, Volume: 29, Issue:4 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult	2013
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. Kardiologia polska, 2013, Volume: 71, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure	2013
Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin. Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:8 Topics: Adolescent; Adult; Aged; Apolipoproteins B; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Renal Dialysis	2013
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. European journal of preventive cardiology, 2013, Volume: 20, Issue:6 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome	2013
Risk of incident diabetes among patients treated with statins: population based study. BMJ (Clinical research ed.), 2013, May-23, Volume: 346 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2013
[Statins after drug discontinuation are usually well tolerated]. Praxis, 2013, Jun-19, Volume: 102, Issue:13 Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Retreatment; Retrospective Studies; Simvastatin	2013
ASK NOT what CRP can do for you. Journal of the American College of Cardiology, 2013, Aug-20, Volume: 62, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Pyrroles	2013
Prevalence and types of persistent dyslipidemia in patients treated with statins. Croatian medical journal, 2013, Volume: 54, Issue:4 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides	2013
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. Przeglad lekarski, 2013, Volume: 70, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires	2013
Are statins 'IDEAL' for non-alcoholic fatty liver disease? Current medical research and opinion, 2014, Volume: 30, Issue:2 Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides	2014
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats. Journal of pharmacological sciences, 2014, Volume: 124, Issue:1 Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation	2014
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events. Clinical therapeutics, 2014, Jan-01, Volume: 36, Issue:1 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides	2014
Statins for millions more? Lancet (London, England), 2014, Feb-22, Volume: 383, Issue:9918 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Participation; Practice Guidelines as Topic; Primary Prevention; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; United Kingdom	2014
Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease. European heart journal, 2014, Volume: 35, Issue:15 Topics: Aged; American Heart Association; Atorvastatin; Cardiovascular Diseases; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Societies, Medical; United States	2014
Sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events. PloS one, 2014, Volume: 9, Issue:3 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comparative Effectiveness Research; Finland; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Propensity Score; Simvastatin	2014
Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention. Annals of the rheumatic diseases, 2015, Volume: 74, Issue:8 Topics: Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Spondylitis, Ankylosing	2015
Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia. Minerva cardioangiologica, 2014, Volume: 62, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Pyrroles; Risk Factors; Treatment Outcome	2014
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vascular health and risk management, 2014, Volume: 10 Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States	2014
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study. Atherosclerosis, 2014, Volume: 236, Issue:1 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States	2014
Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism. Atherosclerosis, 2014, Volume: 236, Issue:2 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cholesterol, LDL; Dose-Response Relationship, Drug; Enzyme Induction; Genes, Reporter; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Risk; Telomerase; Telomere; Telomere Homeostasis	2014
Coronary artery calcium score. JAMA, 2014, Aug-27, Volume: 312, Issue:8 Topics: Atorvastatin; Calcium; Cardiovascular Diseases; Coronary Vessels; Diet; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Middle Aged; Pyrroles; Risk; Tomography, X-Ray Computed; Vascular Calcification	2014
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system. Arquivos brasileiros de cardiologia, 2015, Volume: 104, Issue:1 Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides	2015
Effects of generic substitution on refill adherence to statin therapy: a nationwide population-based study. BMC health services research, 2014, Dec-05, Volume: 14 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Drug Substitution; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Registries; Secondary Prevention; Simvastatin; Sweden; Young Adult	2014
Do statins have a specific drug effect beyond low-density lipoprotein-cholesterol-lowering in the secondary prevention of coronary artery disease? Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Female; Humans; Hypercholesterolemia; Male; Myocardial Infarction; Pravastatin	2015
Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom. Clinical therapeutics, 2015, Apr-01, Volume: 37, Issue:4 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; United Kingdom	2015
Trends in statin consumption and cardiovascular mortality in Croatia 2004-2012. Collegium antropologicum, 2014, Volume: 38 Suppl 2 Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Child; Child, Preschool; Croatia; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Young Adult	2014
Different effects of atorvastatin on metabolic and cardiovascular risk factors in hypercholesterolemic women with normal thyroid function and subclinical hypothyroidism. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2015, Volume: 123, Issue:3 Topics: Adult; Atorvastatin; Cardiovascular Diseases; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypothyroidism; Middle Aged; Risk Factors; Treatment Outcome	2015
Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road? Journal of the American College of Cardiology, 2015, Apr-07, Volume: 65, Issue:13 Topics: Apolipoprotein B-100; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Phospholipids; Pyrroles	2015
PON1 polymorphisms are predictors of ability to attain HDL-C goals in statin-treated patients. Clinical biochemistry, 2015, Volume: 48, Issue:16-17 Topics: Adult; Aged; Aged, 80 and over; Alleles; Aryldialkylphosphatase; Atorvastatin; Brazil; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Genotype; Humans; Male; Middle Aged; Simvastatin	2015
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death. Lipids in health and disease, 2015, Oct-24, Volume: 14 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin	2015
[Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases]. Terapevticheskii arkhiv, 2015, Volume: 87, Issue:9 Topics: Adult; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Inflammation; Interleukin-6; Lipid Metabolism; Matrix Metalloproteinase 3; Middle Aged; Patient Acuity; Rheumatoid Factor; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha	2015
The effect of testosterone on cardiometabolic risk factors in atorvastatin-treated men with late-onset hypogonadism. Pharmacological reports : PR, 2016, Volume: 68, Issue:1 Topics: Aged; Atorvastatin; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; Humans; Hypogonadism; Lipids; Male; Metabolic Diseases; Middle Aged; Risk Factors; Testosterone; Treatment Outcome; Uric Acid	2016
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden. International journal of clinical practice, 2016, Volume: 70, Issue:3 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden	2016
Cholesterol-absorbed in thought. Current opinion in lipidology, 2016, Volume: 27, Issue:2 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Humans; Intestinal Absorption	2016
[FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)]. Revue medicale de Liege, 2016, Volume: 71, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Risk Factors	2016
A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill. Revista espanola de cardiologia (English ed.), 2016, Volume: 69, Issue:6 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Europe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Medication Adherence; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ramipril; Secondary Prevention; Spain	2016
Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy. Annals of the rheumatic diseases, 2016, Volume: 75, Issue:10 Topics: Adult; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Carotid Artery Diseases; Case-Control Studies; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Middle Aged; Risk Factors; Spondylitis, Ankylosing; Treatment Outcome	2016
Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk. Clinical research in cardiology : official journal of the German Cardiac Society, 2016, Volume: 105, Issue:9 Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2016
[Efficiency and safety of generic Atorvastatine in patients at high cardiovascular risk]. Meditsina truda i promyshlennaia ekologiia, 2016, Issue:2 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Risk; Russia	2016
Re: The Effect of Testosterone on Cardiometabolic Risk Factors in Atorvastatin-Treated Men with Late-Onset Hypogonadism. The Journal of urology, 2016, Volume: 195, Issue:6 Topics: Atorvastatin; Cardiovascular Diseases; Hormone Replacement Therapy; Humans; Hypogonadism; Male; Risk Factors; Testosterone	2016
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study). The American journal of cardiology, 2016, 08-15, Volume: 118, Issue:4 Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adiponectin; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Chemokine CCL2; Coronary Artery Disease; Cystatin C; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin; Intercellular Adhesion Molecule-1; Lipoprotein(a); Male; Matrix Metalloproteinase 9; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Neopterin; Osteopontin; Peptide Fragments; Peroxidase; Randomized Controlled Trials as Topic; Receptor for Advanced Glycation End Products; Risk Factors; Secondary Prevention; Vascular Cell Adhesion Molecule-1; Vitamin D	2016
GALECTIN-3 AS A PREDICTOR OF STATIN TREATMENT EFFICACY IN PATIENTS WITH MULTIPLE MYELOMA. Georgian medical news, 2016, Issue:255 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Dyslipidemias; Female; Galectin 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Myeloma; Treatment Outcome	2016
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study. Revista espanola de cardiologia (English ed.), 2017, Volume: 70, Issue:1 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Markov Chains; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Ramipril; Retrospective Studies; Secondary Prevention; Spain	2017
The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care. Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Primary Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin	2016
Invalidation of Atorvastatin Patent Highlights Complex Chinese Patent Law. Trends in pharmacological sciences, 2016, Volume: 37, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; China; Disclosure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Legislation, Drug; Patents as Topic	2016
Different cardiometabolic effects of atorvastatin in men with normal vitamin D status and vitamin D insufficiency. Clinical cardiology, 2016, Volume: 39, Issue:12 Topics: Adult; Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Risk Factors; Vitamin D; Vitamin D Deficiency; Vitamins	2016
The effect of removing funding restrictions for atorvastatin differed across sociodemographic groups among New Zealanders hospitalised with cardiovascular disease: a national data linkage study. The New Zealand medical journal, 2016, Oct-14, Volume: 129, Issue:1443 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Female; Healthcare Disparities; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Information Storage and Retrieval; Male; Middle Aged; Native Hawaiian or Other Pacific Islander; New Zealand; Regression Analysis	2016
Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia. Atherosclerosis, 2016, Volume: 254 Topics: Adult; Atorvastatin; Cardiovascular Diseases; Decision Making; Female; Follow-Up Studies; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Medication Adherence; Patient Education as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome; Young Adult	2016
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. The American journal of cardiology, 2017, Feb-01, Volume: 119, Issue:3 Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke	2017
Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease. Medicina clinica, 2017, Feb-09, Volume: 148, Issue:3 Topics: Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Medication Adherence; Ramipril; Salicylic Acid; Secondary Prevention	2017
Significant association between statin-associated myalgia and vitamin D deficiency among treated HIV-infected patients. AIDS (London, England), 2017, 03-13, Volume: 31, Issue:5 Topics: Adult; Aged; Anti-Retroviral Agents; Atorvastatin; Cardiovascular Diseases; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Retrospective Studies; Rosuvastatin Calcium; Vitamin D Deficiency	2017
Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E Microbiome, 2017, 03-13, Volume: 5, Issue:1 Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics	2017
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Current medical research and opinion, 2008, Volume: 24, Issue:7 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Drug Utilization Review; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Survival Analysis; United States	2008
Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. Archives of cardiovascular diseases, 2008, Volume: 101, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetic Angiopathies; France; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles	2008
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al. Arthritis and rheumatism, 2008, Volume: 58, Issue:8 Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pyrroles; Treatment Outcome; Uric Acid	2008
Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience. Current medical research and opinion, 2008, Volume: 24, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Insurance Claim Review; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors	2008
[Hypertension--does it matter how blood pressure is lowered?]. Ugeskrift for laeger, 2008, Sep-01, Volume: 170, Issue:36 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome	2008
A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease. Diabetes research and clinical practice, 2008, Volume: 82, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Health Maintenance Organizations; Heptanoic Acids; Humans; Preferred Provider Organizations; Pyrroles; Simvastatin; Treatment Outcome; United States	2008
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. The Canadian journal of cardiology, 2008, Volume: 24, Issue:9 Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke	2008
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study. The European journal of health economics : HEPAC : health economics in prevention and care, 2009, Volume: 10, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Europe; Heptanoic Acids; Humans; Markov Chains; Pyrroles; Quality-Adjusted Life Years	2009
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clinic proceedings, 2008, Volume: 83, Issue:12 Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk; Simvastatin; United States	2008
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study. Atherosclerosis, 2009, Volume: 205, Issue:1 Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis	2009
Polycystic ovary syndrome, inflammation, and statins: do we have the right target? The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Testosterone	2009
The TNT study, women and cancer. Heart (British Cardiac Society), 2009, Volume: 95, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory	2009
[Comment from the cardiologic viewpoint]. Praxis, 2009, Feb-04, Volume: 98, Issue:3 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain. Hemodialysis international. International Symposium on Home Hemodialysis, 2009, Volume: 13, Issue:1 Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Regression Analysis; Renal Dialysis; Weight Gain	2009
Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study. Clinical therapeutics, 2008, Volume: 30 Pt 2 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Models, Economic; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic	2008
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. PharmacoEconomics, 2009, Volume: 27, Issue:3 Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome	2009
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada. The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2009,Summer, Volume: 16, Issue:2 Topics: Aged; Atorvastatin; Canada; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis	2009
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid. Iranian journal of kidney diseases, 2009, Volume: 3, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult	2009
Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. Journal of cardiovascular pharmacology, 2009, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endarterectomy; Female; Femoral Artery; Gene Expression; Heptanoic Acids; Humans; Interleukin-8; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Peripheral Vascular Diseases; Pyrroles; Receptor, Angiotensin, Type 1; Triglycerides	2009
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea. Clinical therapeutics, 2009, Volume: 31, Issue:10 Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Korea; Male; Markov Chains; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Risk Factors	2009
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population. Mayo Clinic proceedings, 2009, Volume: 84, Issue:12 Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Benefit Plans, Employee; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Simvastatin; United States	2009
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. Clinical drug investigation, 2010, Volume: 30, Issue:2 Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides	2010
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach? Journal of the American College of Cardiology, 2009, Dec-15, Volume: 54, Issue:25 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors	2009
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. Journal of atherosclerosis and thrombosis, 2010, Jun-30, Volume: 17, Issue:6 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha	2010
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States	2010
Charting new territory by simulated modeling of a clinical trial. Clinical journal of the American Society of Nephrology : CJASN, 2010, Volume: 5, Issue:5 Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome	2010
The utility of observational studies in clinical decision making: lessons learned from statin trials. Postgraduate medicine, 2010, Volume: 122, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin	2010
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. BMC cardiovascular disorders, 2010, Jun-17, Volume: 10 Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States	2010
Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs & aging, 2010, Jul-01, Volume: 27, Issue:7 Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Time Factors	2010
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk. American journal of therapeutics, 2011, Volume: 18, Issue:6 Topics: Absenteeism; Adult; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Employment; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Simvastatin	2011
Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy. American journal of therapeutics, 2012, Volume: 19, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Time Factors; Treatment Outcome	2012
Statin wars: efficacy vs. cost. International journal of clinical practice, 2011, Volume: 65, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin	2011
Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care. International journal of clinical practice, 2011, Volume: 65, Issue:2 Topics: Adult; Aged; Atorvastatin; Body Mass Index; Cardiovascular Diseases; England; Family Practice; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin	2011
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy? European journal of preventive cardiology, 2012, Volume: 19, Issue:3 Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome	2012
Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes. Angiology, 2011, Volume: 62, Issue:7 Topics: Adult; Aged; Angiogenic Proteins; Asian People; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Diabetes Mellitus; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Pyrroles; von Willebrand Factor; White People	2011
The cholesterol ester transfer protein inhibitor, anacetrapib. Current opinion in lipidology, 2011, Volume: 22, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Oxazolidinones; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids in health and disease, 2011, Jun-10, Volume: 10 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult	2011
The value of atorvastatin over the product life cycle in the United States. Clinical therapeutics, 2011, Volume: 33, Issue:10 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Utilization Review; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Simvastatin; Time Factors; United States	2011
Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin. The American journal of geriatric pharmacotherapy, 2011, Volume: 9, Issue:6 Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Multivariate Analysis; Pyrroles; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; United States	2011
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Primary care respiratory journal : journal of the General Practice Airways Group, 2012, Volume: 21, Issue:1 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin; Treatment Outcome	2012
Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-pres Geriatrics & gerontology international, 2012, Volume: 12 Suppl 1 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Proportional Hazards Models; Pyrroles	2012
Anti-inflammatory effects of perioperative statin therapy. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2012, Volume: 59, Issue:6 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles	2012
Perioperative statin therapy: understanding the evidence in a Bayesian context. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2012, Volume: 59, Issue:6 Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles	2012
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. Journal of medical economics, 2012, Volume: 15, Issue:6 Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides	2012
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice. Pharmacotherapy, 2012, Volume: 32, Issue:7 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2012
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain. Journal of medical economics, 2012, Volume: 15 Suppl 1 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides	2012
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:3 Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin	2013
A piece of my mind: A pain in the tuches. JAMA, 2012, Dec-19, Volume: 308, Issue:23 Topics: Anticholesteremic Agents; Atorvastatin; Buttocks; Cardiovascular Diseases; Heptanoic Acids; Humans; Medication Adherence; Mortality, Premature; Muscular Diseases; Pain; Physicians; Pyrroles; Sciatica; Self Care	2012
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2002, Volume: 12, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides	2002
[Absolutely essential in cardiovascular high risk patients. Statins--more than only anticholesteremic drugs]. MMW Fortschritte der Medizin, 2002, Jun-27, Volume: 144, Issue:26 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk; Survival Rate	2002
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases]. Kardiologiia, 2002, Volume: 42, Issue:3 Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines	2002
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins? Archives of internal medicine, 2003, Feb-10, Volume: 163, Issue:3 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Cost of Illness; Cost-Benefit Analysis; Direct Service Costs; Efficiency; Female; Health Care Costs; Health Expenditures; Heptanoic Acids; Humans; Hypolipidemic Agents; Life Expectancy; Male; Middle Aged; Primary Prevention; Pyrroles; Sensitivity and Specificity	2003
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation, 2003, Apr-01, Volume: 107, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Research; Ticlopidine	2003
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 2003, Apr-02, Volume: 289, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine	2003
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Sex Factors	2003
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles	2003
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hypertension; Pyrroles; Research Design	2003
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Risk	2003
ASCOT-LLA: questions about the benefits of atorvastatin. Lancet (London, England), 2003, Jun-07, Volume: 361, Issue:9373 Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black People; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Risk Factors	2003
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2003, Jun-24, Volume: 168, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors	2003
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based Revue medicale de Liege, 2003, Volume: 58, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom	2003
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Nephron. Clinical practice, 2003, Volume: 95, Issue:4 Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors	2003
Intensive statin therapy--a sea change in cardiovascular prevention. The New England journal of medicine, 2004, Apr-08, Volume: 350, Issue:15 Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases. Medical hypotheses, 2004, Volume: 62, Issue:4 Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin	2004
Statins in rheumatoid arthritis--two birds with one stone? Lancet (London, England), 2004, Jun-19, Volume: 363, Issue:9426 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors	2004
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Archives of neurology, 2004, Volume: 61, Issue:6 Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone	2004
Clinical significance of the atorvastatin-clopidogrel drug-drug interaction. Circulation, 2004, Aug-10, Volume: 110, Issue:6 Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Sample Size; Ticlopidine	2004
Battle of the statins, or how the news media can change patient care. JAAPA : official journal of the American Academy of Physician Assistants, 2004, Volume: 17, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles	2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England journal of medicine, 2004, Aug-12, Volume: 351, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides	2004
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association]. Revue medicale de Liege, 2004, Volume: 59, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms	2004
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease. Pharmacological research, 2005, Volume: 51, Issue:1 Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Sterols	2005
[CARDS confirms usefulness of LDL lowering in type 2 diabetics]. Praxis, 2004, Oct-27, Volume: 93, Issue:44 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Time Factors	2004
Combined hyperlipidemia in a single subject with tetraplegia: ineffective risk reduction after atorvastatin monotherapy. The journal of spinal cord medicine, 2004, Volume: 27, Issue:5 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cervical Vertebrae; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Male; Odds Ratio; Pyrroles; Spinal Cord Injuries; Treatment Failure; Triglycerides; Wounds, Gunshot	2004
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals? The New England journal of medicine, 2005, Apr-07, Volume: 352, Issue:14 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk	2005
Controversies in antiplatelet therapy for patients with cardiovascular disease. Circulation, 2005, May-03, Volume: 111, Issue:17 Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pyrroles	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Simvastatin	2005
Intensive lipid lowering with atorvastatin in coronary disease. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Rhabdomyolysis	2005
Ready, aim, treat to hit new cholesterol targets. Heart advisor, 2005, Volume: 8, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Reference Values	2005
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly]. MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors	2005
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too]. MMW Fortschritte der Medizin, 2005, Aug-18, Volume: 147, Issue:33-34 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Triglycerides	2005
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. European journal of clinical pharmacology, 2005, Volume: 61, Issue:9 Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors	2005
[Considerable LDL lowering is advantageous]. MMW Fortschritte der Medizin, 2005, Sep-01, Volume: 147, Issue:35-36 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Placebos; Pyrroles; Risk; Risk Factors; Triglycerides	2005
Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2005, Volume: 25, Issue:5 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Acids; Female; Heptanoic Acids; Humans; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Risk; Treatment Outcome	2005
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al. Diabetes care, 2005, Volume: 28, Issue:10 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic	2005
Differences between statins on clinical endpoints: a population-based cohort study. Current medical research and opinion, 2005, Volume: 21, Issue:9 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome	2005
The pharmaco-economics of peri-operative statin therapy. Anaesthesia, 2005, Volume: 60, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Monitoring; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Perioperative Care; Prospective Studies; Pyrroles; State Medicine; United Kingdom; Vascular Surgical Procedures	2005
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?]. MMW Fortschritte der Medizin, 2005, Sep-29, Volume: 147, Issue:39 Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure	2005
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis. The New England journal of medicine, 2005, Oct-27, Volume: 353, Issue:17 Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke	2005
The IDEAL cholesterol: lower is better. JAMA, 2005, Nov-16, Volume: 294, Issue:19 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin	2005
Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells. Clinical chemistry and laboratory medicine, 2005, Volume: 43, Issue:12 Topics: Anti-Inflammatory Agents; Atorvastatin; Cardiovascular Diseases; Concanavalin A; Dose-Response Relationship, Drug; Heptanoic Acids; Homocystine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Neopterin; Oxidative Stress; Phytohemagglutinins; Pyrroles	2005
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv International journal of cardiology, 2006, Jun-16, Volume: 110, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets	2006
A rationale for combination therapy in risk factor management: a mechanistic perspective. The American journal of medicine, 2005, Volume: 118 Suppl 12A Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Disease Management; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Humans; Nitric Oxide; Pyrroles; Risk Factors	2005
Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease. Current atherosclerosis reports, 2006, Volume: 8, Issue:1 Topics: Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk; Triglycerides	2006
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. American heart journal, 2006, Volume: 151, Issue:3 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin	2006
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation, 2006, Mar-21, Volume: 113, Issue:11 Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine	2006
Statins and antioxidant vitamins: should co-administration be avoided? Journal of the American College of Cardiology, 2006, Mar-21, Volume: 47, Issue:6 Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Calcinosis; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Vitamin E	2006
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. American heart journal, 2006, Volume: 152, Issue:2 Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Pyrroles; Quebec; Retrospective Studies; Stents; Ticlopidine	2006
Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis? Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:2 Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis	2006
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease. Nature clinical practice. Nephrology, 2006, Volume: 2, Issue:7 Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure	2006
[HIV infection: from Pneumocystis to statins]. Medicina clinica, 2006, Jul-15, Volume: 127, Issue:7 Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors	2006
Does the metabolic syndrome help to select patients requiring high statin dose? Lancet (London, England), 2006, Sep-09, Volume: 368, Issue:9539 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Incidence; Metabolic Syndrome; Patient Selection; Pyrroles; Risk Assessment; Risk Factors	2006
Statin therapy after stroke or transient ischemic attack. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases	2006
Statin therapy after stroke or transient ischemic attack. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis	2006
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2006, Volume: 26, Issue:6 Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia	2006
The failure of torcetrapib: was it the molecule or the mechanism? Arteriosclerosis, thrombosis, and vascular biology, 2007, Volume: 27, Issue:2 Topics: Angina Pectoris; Animals; Anticholesteremic Agents; Atorvastatin; Cardiac Output, Low; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Mice; Myocardial Revascularization; Pyrroles; Quinolines; Rabbits; Treatment Failure	2007
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia, 2007, Volume: 50, Issue:4 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Models, Economic; Primary Prevention; Pyrroles; Quality-Adjusted Life Years	2007
[Effects of atorvastatin on hyperlipidemia in kidney disease patients]. Nihon Jinzo Gakkai shi, 2007, Volume: 49, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis	2007
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. European heart journal, 2007, Volume: 28, Issue:12 Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quality of Life; Simvastatin; Survival Rate; Time Factors	2007
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure]. Nederlands tijdschrift voor geneeskunde, 2007, Mar-03, Volume: 151, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke	2007
[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine]. Likars'ka sprava, 2006, Issue:8 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Body Weight; Cardiovascular Diseases; Heptanoic Acids; Humans; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Rural Health; Rural Population; Ukraine	2006
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective. Current medical research and opinion, 2007, Volume: 23, Issue:7 Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States	2007
Summaries for patients. High- or low-dose atorvastatin in elderly patients with stable coronary artery disease. Annals of internal medicine, 2007, Jul-03, Volume: 147, Issue:1 Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides	2007
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids, 2007, Volume: 42, Issue:11 Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regression Analysis; Risk Factors; Triglycerides	2007
A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins". Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9 Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic	2007
American Heart Association--Scientific Sessions 2007. Part 1. IDrugs : the investigational drugs journal, 2008, Volume: 11, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Drugs, Investigational; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Molecular Structure; Pyrroles	2008
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench. Cardiovascular research, 2008, Mar-01, Volume: 77, Issue:4 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Quinolines; Treatment Outcome	2008
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome. Pharmacological research, 2008, Volume: 57, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome	2008
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Mortality; Pyrroles	2008
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Research Design	2008
Analyzing the results of the treating to new targets study. Annals of internal medicine, 2008, Feb-19, Volume: 148, Issue:4 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles	2008
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Journal of the cardiometabolic syndrome, 2008,Winter, Volume: 3, Issue:1 Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke	2008
Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clinical therapeutics, 2008, Volume: 30, Issue:1 Topics: Atorvastatin; Cardiovascular Diseases; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Primary Prevention; Proportional Hazards Models; Pyrroles; Simvastatin; United States	2008
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:5 Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States	2008
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. PharmacoEconomics, 2008, Volume: 26, Issue:4 Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years	2008
The failure of torcetrapib: is there a case for independent preclinical and clinical testing? Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Pyrroles; Quinolines; Research Design	2008
Torcetrapib and coronary events. The New England journal of medicine, 2008, Apr-24, Volume: 358, Issue:17 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure	2008
The nature of the statins. Circulation, 2000, Feb-29, Volume: 101, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2000
Is C-reactive protein an additional, surrogate end-point for statin treatment? European heart journal, 2002, Volume: 23, Issue:10 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Sensitivity and Specificity; Triglycerides	2002